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Abstract
The common bean (Phaseolus vulgaris L.) plays an important role in human nutrition,
especially among low-income people in developing countries, primarily due to the high
protein content of this legume, ranging from 19% to 27%. Previous studies have indicated
that cooked bean bio-active peptides also exhibit anti-diabetic, antioxidant, and antimicrobial
properties. It is hypothesized that small peptides (600-1000 Da) derived from different
common bean strains are primarily responsible for eliciting bio-active effects. This project
evaluated protein isolated extracts from 4 different strains of common bean for antioxidant
capacity, anti-diabetic effects, and antimicrobial activity. Surprisingly, the bio-active
compounds identified in this research revealed that the anti-diabetic effects of common bean
extracts originate from lipids, not peptides. The findings that some bio-active properties of
common bean extracts are of lipid origin are novel and previously unrecognized. Future in
vitro and in vivo experiments are required to further identify and characterize the bio-active
molecules from common bean strains that promote human health benefits.
Keywords: Phaseolus vulgaris, bioactive peptides, lipids, DPP-IV inhibition, antioxidant,
antimicrobial properties
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Summary for Lay Audience
The common bean (Phaseolus vulgaris L.) plays an important role in human nutrition,
especially among low-income people in developing countries, primarily due to the high
protein content of this legume, ranging from 19% to 27%. Peptides are the intermediate
products of protein digestion that occur in the human gastrointestinal system, and have
unique physiological activities and beneficial properties to humans, which the original intact
proteins do not have. This study focused on common bean small peptides, generated by a
process that mimics cooking followed by digestion in the stomach. In particular, the
antioxidant, anti-diabetic, and antimicrobial properties of extracts enriched with small bean
peptides were assessed. We compared 4 different strains of common bean, which are
genetically related but different in storage protein content, extracted proteins, and simulated
the human gastrointestinal digestion process to generate small peptides. Peptides isolated
from each bean strain were analyzed using multiple antioxidants, anti-diabetic, and
antimicrobial tests. This study also looked further into specifically identifying the bio-active
compounds in cooked common bean that exhibited anti-diabetic properties.
Surprisingly, the bioactive compounds identified in this research revealed that the antidiabetic effects derived from common bean extracts appear to originate from lipids, not
peptides. The findings that some bio-active properties of common bean extracts are of lipid
origin are novel and previously unrecognized. Results of the study also showed that bioactive
compounds exhibiting antimicrobial properties were probably also not peptides. These newly
identified compounds may provide new antibacterial resources against bacterial drug
resistance. However, more information is required to identify the nature of the bioactive
molecules precisely. Studies of antioxidant capacity suggest that the bioactive molecules
were probably a mixture of small peptides. Future in vitro and in vivo experiments are
required to further identify and characterize the bio-active molecules from common bean
strains that promote human health benefits.
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Chapter 1: Introduction
1.1 Common bean
As one of the most favoured food worldwide, the common bean (Phaseolus vulgaris L.)
accounts for 50% of the grain legume consumption for humans (McClean et al., 2004).
Botanically, P. vulgaris is a dicotyledonous annual plant, and it is a true diploid with 11
chromosomes (2n = 2x = 22, n=11) belonging to the Family Fabaceae, and domesticated and
dispersed from their wild-type ancestor originating in Mesoamerica and the Andes (Koenig
and Gepts, 1989). The genome size of P. vulgaris is small [580 million base pair
(MBp)/haploid genome] and is comparable to that of rice (340 560 MBp/haploid genome),
which is the smallest genome among economically important plants recognized by the United
State Department of Agriculture (USDA) (Broughton et al., 2003; Gepts et al., 2008). Most
common beans are self-pollinating plants; however, cross-pollination may occur in some realworld situations; for example, when the stigma grows overlength and is touched by
pollinating insects (Ibarra-Perez et al., 1997). Although common beans are similar
botanically, the seed size (about 7-16 mm long and without endosperm), colour (white, red,
black, brown, or mottled), and shape (oval, oblong or kidney shape) vary greatly (Katungi et
al., 2009). With a long cultivation history, over 600 known varieties of common beans are
grown globally, 62 of them being recognized as commercial market classes, including Pinto,
Navy, Small White, Cranberry, and Kidney (Azarpazhooh and Boye, 2012). The current
distribution of the wild common bean is from northern Mexico to Northwestern Argentina,
and there are two major eco-geographical gene pools: Mesoamerica and the Andes (Bitocchi
et al., 2012).
As traditional plants that have existed for over 7000 years globally (Câmara et al., 2013), the
common beans always have a worthy place in human diets. Based on the Food and
Agriculture Organization in 2018 (http://www.fao.org/faostat/en/#data/QC, accessed 18 April,
2020), world production of the dry bean was 30,434,280 tonnes, which has increased by
almost 120% since 1980. India is the largest producer, estimated at approximately 6.22
million tonnes, followed by Myanmar, Brazil, the USA, and China. Canada was ranked 16th
in 2018, with a common bean production of 341,110 harvested tonnes. By contrast, according
to international trade data from the

Canada was

the 3rd largest exporter in the world of kidney beans and white pea beans dried shelled in
2018, sharing

trade at $147 million, second only to the United States
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(15.9%, $258 million) and China (14.5%, 235 million), with 44.2% of exported beans going
to

the

United

Kingdom

($64.8

million)

(https://oec.world/en/visualize/tree-

map/hs92/export/can/all/2071333/2018/, accessed 7 June, 2020)

1.2 Nutrients of common bean
1.2.1 The nutrient value of the common bean
According to epidemiological studies, diets rich in legumes are positively linked to longevity,
improved heart health, and reduced risk for many types of cancers (Câmara et al., 2013). The
common bean is rich in carbohydrates (60%), proteins (19%-27%), fibre, and it is a good
source of unsaturated fatty acids, vitamin B complex, and a variety of chemical trace
elements (Montoya et al., 2010). Because of the high amount of protein and dietary fibre but
the very low-fat content in common beans (approximately two times higher protein than
major cereals, Table 1 - 1), they became a staple food for low-income people in rural and
urban areas in many developing countries where animal proteins are expensive and proteinenergy malnutrition is prevalent (Lima et al., 2005). Because of the high content of proteins
in common beans, this project was focused on how these proteins benefit the human body
after cooking processes.

Table 1 - 1: Comparison of nutritional profiles of dry beans with major grains (per
100g). Adapted from the USDA (https://fdc.nal.usda.gov/, accessed 19 April, 2020)
Energy (Kcal)
Protein (g)
Total lipid (fat) (g)
Carbohydrates (g)
Fiber, total dietary(g)
Sugars
Calcium (mg)
Iron (mg)
Potassium (mg)
F

Dry Beans
337
22.33
1.5
60.75
15.3
3.88
147
5.49
1185
364

Wheat
342
11.31
1.71
75.9
12.2
0.41
32
4.56
355
38

Oat
379
13.15
6.52
67.7
10.1
0.99
52
4.25
362
32

Corn
365
9.42
4.74
74.26
7.3
0.64
7
2.71
287
19

Sorghum
329
10.62
3.46
72.09
6.7
2.53
13
3.36
363
20
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1.2.2 Seed storage proteins of common bean
1.2.2.1

Seed storage proteins of common bean

Despite the high protein content of the common bean, its protein quality is sub-optimal due to
the low amount of two nutritionally sulfur amino acids: cysteine (Cys) and methionine (Met,
essential amino acid) (Pandurangan et al., 2015). The low sulfur amino acid content in the
common bean is primarily attributed to high globulin levels, which acts as storage proteins
for subsequent seed germination. As a sink for nitrogen, globulins are rich in nitrogen-rich
amino acids, which are degraded after germination to provide nitrogen for the construction of
new proteins (Shewry et al., 1995). However, globulin proteins lack the two sulfur-containing
amino acids (Cys and Met) (Boulter and Croy, 1997). Globulins can be further divided into
11S globulin (legumin) and 7S globulin (phaseolin) fractions by their sedimentation
coefficients (Marsolais et al., 2010; Shewry et al., 1995; Taylor et al., 2008).
Phaseolin, composed of 2 to 6 polypeptides, is the major globulin in common beans with
molecular weights ranging from 43 to 54 kDa (Osborn and Brown, 1988). There are three
major types of phaseolin in different common bean varieties, which first identified by Brown
et al. (1981) using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
and named after their cultivars of origin

.

According to Acquaah et al. (1994), 49.2% of common bean accessions from Malawi in
Africa had the Tendergreen type phaseolin, 24.8% had the Contender type, and 23.5%
had the Sanilac type. Lectins are seed storage proteins found in common bean, with
molecular weights between 27 and 37 kDa (Sathe, 2002). P

-amylase

inhibitors belong to lectins, and each contributes about 10% of seed protein, respectively
(Marsolais et al., 2010). Lectins are anti-nutritional factors, which means they can block the
absorption of nutrients by inhibiting gastrointestinal digestive enzymes or cell agglutinating
activities (Vasconcelos and Oliveira, 2004). Lectins are compounds designed to prevent
bacterial infections and insect consumption (Peumans and Van Damme, 1995), which is why
they are hard to be absorbed in the raw state. However, they are thermolabile after proper
cooking processes (Vasconcelos and Oliveira, 2004). Arcelin is another seed storage protein
found in wild bean varieties (Osborn et al., 1986) and acts as a growth inhibitor on bruchid
pests (Marsolais et al., 2010; Velten et al., 2007).
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1.2.2.2

Improvement of protein quality in grain legumes

During the past decades, attempts have been made through breeding programs or transgenic
approaches to improve the protein quality of the grain legumes due to the low amount of two
nutritionally sulfur amino acids Cys and Met (Aragão et al., 1999; Bliss and Brown, 1983;
Gepts and Bliss, 1984; Taylor et al., 2008). The principal target has usually been phaseolin
since it is the major seed storage protein that constitutes up to 50% of the total seed protein in
commercial cultivars while deficient in Met and Cys (Marsolais et al., 2010). Taylor et al.
(2008) found that the reduction of the non-protein amino acid S-methylcysteine in
commercial common bean cultivars, resulted in the preferential increase in the concentration
of Met and Cys in seed storage protein-deficient lines. This discovery gave a new way to
improve the protein quality of commercial common bean cultivars.

1.2.2.3

Peptides

Peptides are an intermediate product of protein degradation and have unique physiological
activities and beneficial properties to humans, which the original protein and individual
amino acids do not have. In common bean peptides, these benefits include anti-inflammatory
(García-Lafuente et al., 2014), anti-diabetic (González-Montoya et al., 2018), antioxidant
(Carrasco-Castilla et al., 2012), anti-hypertensive (Garcia-Mora et al., 2016) and anticarcinogenic effects (Câmara et al., 2013). In this project, we primarily focused on
antioxidant, anti-diabetic, antimicrobial, and anti-lipogenic properties of common bean
peptides.

1.3 The non-nutritional value of common bean peptides
1.3.1 The importance of antioxidants in the human body
The antioxidant capacity of natural foods to counter the harmful effects of free radicals has
attracted increased attention (Lobo et al., 2010). Reactive oxygen species (ROS) are unstable
molecules containing oxygen that can promote the oxidation of various biological
macromolecules. Cellular oxidative stress occurs when there is either an increased production
of ROS, or inadequate levels of dietary, or endogenous antioxidants. Elevated ROS can

5

damage DNA, RNA, lipids and proteins, potentially leading to the death of cells, tissues, and
organs, and is believed to be a contributing factor to multiple diseases such as cardiovascular
diseases, chronic kidney diseases, and cancer (Liguori et al., 2018). Antioxidants can capture
and neutralize free radicals, thereby preventing cellular oxidative damage (Oseguera-Toledo
et al., 2011). Glutathione, an abundant thiol-containing tripeptide produced in most
organisms, can undergo oxidation and reduction cycles to detoxify ROS (Pompella et al.,
2003). According to Zou et al. (2016), antioxidant capacity in the Pinto bean derived peptide
was mainly found in molecular weight fractions < 3 kDa.

1.3.2 Diabetes and bean peptides
Diabetes mellitus is a severe chronic disease worldwide that occurs when the human body
cannot lower the blood sugar levels either because pancreatic -cells do not produce enough
insulin or the body does not respond to the produced insulin (Nair et al., 2013). In 2014, over
422 million adults were diagnosed as diabetic (Zhou et al., 2017). Moreover, in 2016,
diabetes was identified as the 7th leading cause of death globally. Diabetes is broadly
classified under three categories of hyperglycemia, including type 1 diabetes, type 2 diabetes,
and

gestational

diabetes

(https://www.who.int/news-room/fact-sheets/detail/diabetes,

accessed on April 3, 2019). Type 1 diabetes, formerly known as insulin-dependent diabetes,
occurs mainly in children or adolescents. It is characterized by a severe lack of insulin
secretion in pancreatic cells, which means insulin must be injected daily; otherwise, it is lifethreatening (Al-Goblan et al., 2014). Type 2 diabetes, initially called non-insulin-dependent
or adult-onset diabetes,

use insulin effectively, and

usually occurs after 35 to 40 years of age, accounting for more than 90% of the diabetic
patients (Ginter and Simko, 2013). The difference between type 2 diabetes and type 1
diabetes is that the ability to produce insulin in patients with type 2 diabetes is not entirely
lost; some patients even produce too much insulin from pancreatic -cells. However, the
cellular insulin response is weak, resulting in insulin resistance (Kahn et al., 2006).
Gestational diabetes mellitus (GDM) is a particular case of type 2 diabetes that can occur
during pregnancy, with elevated blood glucose levels that are higher than usual but do not
reach the diagnostic value of diabetes. There are more than 200,000 cases of GDM annually,
representing approximately 7% of the total pregnancies (American Diabetes Association,
2004). In this project, we focused on how the common bean digested peptides could help
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inhibit dipeptidyl peptidase-4 (DPP-IV) activity, a target of several anti-diabetic medications
to lower the blood sugar level (Matteucci and Giampietro, 2009), as a treatment for type 2
diabetes.
DPP-IV is a serine exopeptidase located at the cell surface, with a primary function to affect
extracellular proteins by cleaving target polypeptides that have alanine or proline at the
penultimate end of the N-terminus, and most cleaved substrates will lose their biological
activity (Matteucci and Giampietro, 2009). DPP-IV can cleave a broad range of substrates,
including incretins, Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP). Incretins promote the release of insulin and inhibit glucagon (a hormone
with a promotion of glycogenolysis and gluconeogenesis, resulting in the increase of glucose
in the blood) release when blood sugar levels are elevated, thereby lowering blood glucose
levels. Inhibitors that block the DPP-IV enzyme and prevent the inactivation of incretins have
been evaluated for their use in treating type 2 diabetes mellitus (Röhrborn et al., 2015).
According to Oseguera-Toledo et al. (2015), common bean derived peptides with molecular
weight <1 kDa have a strong ability to promote DPP-IV inhibition and enhanced glucosestimulated insulin secretion. The -amylase and -glucosidase enzymes are also key enzymes
associated with type 2 diabetes since they catalyze the starch hydrolysis into glucose (Nair et
al., 2013). The -amylase is predominately found within the human body in saliva and
pancreatic juice

-glucosidase is located in the brush border of the small intestine; these

enzymes work together to break down starch and disaccharides into glucose (Bonnefond et
al., 2017; Ramkumar et al., 2010). The inhibitors for these two enzymes are also called
are now used as anti-diabetic medicines that help to lower post-meal
blood glucose levels (Zhang et al., 2020). Research has also shown that common bean
derived peptides can significantly reduce the digestion of starchy food (69.2% - 93.3%) by
inhibiting the activity of -amylase and -glucosidase enzymes, further highlighting their
potential use as a functional or medicinal food for type 2 diabetes (Mojica et al., 2015; Obiro
et al., 2008; Zhang et al., 2020).

1.3.3 Obesity and bean peptides
Obesity is also a global public health problem, and has a strong relationship with insulin
resistance and type 2 diabetes (Al-Goblan et al., 2014). The underlying cause of obesity and
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overweight, in general, is the energy imbalance between calorie intake and expenditure, and it
is recognized as an independent predictor of non-communicable diseases such as
cardiovascular disease and diabetes (Flegal et al., 2005). The World Health Organization
reported that in 2016, over 1.97 billion and 650 million adults worldwide were expected to be
overweight

and

obese,

respectively

(https://www.who.int/news-room/fact-

sheets/detail/obesity-and-overweight, accessed on Feb 25, 2019). Martinez-Villaluenga et al.
(2008) showed

-conglycinin, a major seed storage

protein in soybean, can effectively inhibit lipid accumulation in 3T3-L1 adipocytes in vitro,
thus suggesting that the epidemic of obesity/overweight may be mitigated by consumption of
bean derived proteins.

1.3.4 Antimicrobial
The first antibiotic, penicillin, was accidentally discovered by Alexander Fleming on
September 3, 1928 (Aminov, 2010). Since then, various antibiotics have been widely used to
treat human infectious diseases. Antibiotics are known to have the initial strength of being
effective in treating pathogenic bacteria, but they lose their antimicrobial ability over time
due to the abuse of various antibiotics (Lei et al., 2019). The abuse of antibiotics can promote
drug-resistant bacteria, which leads to severe health problems worldwide and causes over
700,000 deaths annually (Pokharel et al., 2020). Drug resistance in bacteria has now become
an urgent problem, and it was the theme of the World Health Day 2011
. Thus, the development of new antibiotics or other new
antibacterial resources has become an urgent need and is catching more attention from
scientists worldwide.
Antimicrobial peptides (AMPs) are part of the innate immune system and can be found
among almost all kinds of organisms. AMPs are a class of small peptides that are 10 to 60
amino acids in length, and most of them are positively charged (average net charge: 3.32)
(Huan et al., 2020; Jenssen et al., 2006). AMPs can work efficiently against bacteria, fungi,
parasites, and viruses by binding to and disrupting the outer membrane. Because they are not
easily affected by the evolution of bacterial resistance, AMPs are considered a promising
class of new antibiotics (El Shazely et al., 2020). Plant AMPs can be isolated from roots,
stems, leaves, flowers, fruits, and seeds; they are usually rich in cysteine residues which form
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multiple disulfides bridges to enhance structural stability and can be classified into thionins,
defensins, hevein- and knottin-type peptides, and lipid transfer proteins (Meneguetti et al.,
2017; Nawrot et al., 2014). During the past decades, plant AMPs have attracted the attention
of the pharmaceutical industry and the scientific community, and their biotechnological
potential for the treatment of human diseases has been demonstrated (de Souza Cândido et al.,
2014; Meneguetti et al., 2017). For example, Franco et al. (2006) found that AMPs derived
from the cowpea (Vigna unguiculate) defensin II (CP-thionin II) protein can be effective
against Staphylococcus aureus, which is a gram-positive bacterium that causes major
infections in the human body, including abscesses of the skin and sinusitis of the respiratory
system (Lowy, 1998). Thus, it can be envisaged that plant AMPs will become valuable
therapeutic tools against pathogens to protect human health in the next few years.

1.4 Agronomic characteristics of the bean germplasm used in
this project
In this study, the common bean strains Sanilac, SARC1, SMARC1-PN1, and SMARC1NPN1, were used to characterize and identify the bioactive peptides that exhibit antioxidant
capacity, anti-diabetic effects, antimicrobial and anti-lipogenic ability. Sanilac is a
commercial cultivar containing two major seed storage proteins: phaseolin and lectins.
SARC1 is a hybridized variety between Sanilac and a wild accession G12282 containing
arcelin-1 protein, so it has all three major seed storage proteins: arcelin-1, phaseolin, and
lectins. In addition, the introduction of arcelin-1 is associated with an approximately 3-fold
decrease of phaseolin levels in SARC1, thus arcelin-1 functions as the main storage protein
rather than phaseolin (Marsolais et al., 2010). The SARC1 line was further introgressed with
recessive mutation varieties

Phaseolus coccineus

and

Great Northern 1140 , which

conferred a deficiency in phaseolin and lectins, respectively. SMARC1-PN1 contains arcelin
and lectins but lacks phaseolin, while SMARC1N-PN1 lacks all three major seed storage
proteins (Figure 1 - 1). The genomes of all three hybridized lines share 85% identity with
their parental cultivar Sanilac (Taylor et al., 2008). The total seed protein content for all four
varieties is not significantly different. Deficiencies in major seed storage proteins are
correlated with an increase in the content of sulfur-rich proteins (Marsolais et al., 2010).
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Figure 1 - 1: Protein extracts from Sanilac, SARC1, SMARC1-PN1 and
SMARC1N-PN1. Cultivars were resolved by SDS-PAGE, followed by Commassie
Blue staining to reveal the prominent seed storage proteins as indicated by arrows:
Phaseolin (47.5 kDa), arcelin-1 (35 kDa), and Phytohemagglutinin (32 kDa) [Adapted
with permission from Taylor et al. (2008). Copyright (2021) American Chemical
Society]
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1.5 Hypothesis
I hypothesize that small bio-peptides (600-1000 Da) derived from common bean proteins
during cooking/digestion conditions will exhibit antioxidative, anti-lipogenic, and
antimicrobial properties, in addition to inhibitory effects on DPP-IV,

-amylase,

-

glucosidase enzymatic activity.

1.6 Research objectives
1. Extract and purify protein isolates from common beans and mimic the cooking process
and human digestion to generate small bio-peptides.
2. Characterize the antioxidant properties of common bean derived small bio-peptides using
in vitro assays.
3. Determine if common bean small bio-peptide isolates can inhibit DPP-IV in vitro.
4. Assess the capacity of common bean small bio-peptides to inhibit starch digestion.
5. Evaluate the potential of common bean small bio-peptides to inhibit fat accumulation in
cultured 3T3-L1 adipocytes.
6. Test antimicrobial ability of common bean small-bio-peptide by bacterial culture.
7. Identify bioactive compounds that inhibit DPP-IV enzymic activity.
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Chapter 2: Materials and Methods
2.1 Plant material
The Common bean (Phaseolus vulgaris L.) genotype Sanilac, SARC1, SMARC1-PN1 and
SMARC1N-PN1 seeds were sown and germinated in vermiculite, and 12-day old seedlings
were transplanted into 17 × 20 cm plastic pots containing Promix BX potting medium
(Premier Tech Horticulture, Québec, Canada). Plants were grown in growth cabinets
(Environmental Growth Chambers, Chagrin Falls, OH, USA) and regularly fertilized with a
nitrogen, phosphorous, and potassium (20-20-20) mixture. The temperature in the growth
-2

cabinets was set at 24 ºC under 16 h light (300-

s-1) and 18 ºC under 8 h

dark (Pandurangan et al., 2012).

2.2 Determination of peptide concentration of the cooked beans
2.2.1 Protein isolates extraction
Four common bean samples (20 g of each variety) were cooked in 350 mL boiling water for 1
h and 15 min, strained, and beans were cooled down to room temperature. The pH of a 1:5
(w/v) bean paste/water ratio solution was adjusted to 8.0 with 0.1M NaOH, and then the
solution was
15,000 ×

at
The remaining pellet was extracted twice under the same conditions to

maximize the protein extraction yield, and all extracts were mixed. The supernatants were pH
adjusted to 4.3 with 0.1 M HCl, then centrifuged for 30 min at 20,000 ×
protein isolates (BPI) pellet were lyophilized in a LABCONCO FreeZone Freeze Dry System
(Kansas, MO, USA). Dried BPI was stored at -20

until further analysis (Mojica and de

Mejía, 2016).

2.2.2 Simulation of gastrointestinal digestion
To mimic gastrointestinal digestion of the common bean proteins, the BPI was resuspended
in water (1:50 w/v), and digested using pepsin (EC 3.4.23.1; > 2,500 units/mg; purchased
from Sigma-Aldrich, St. Louis, Mo., U.S.A.) for 2 h at

in a 1: 75.6 (w/w) enzyme: BPI

ratio (pH 2.0), followed by digestion with pancreatin (EC 232-468-9, 8×USP, purchased
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from Sigma-Aldrich, St. Louis, Mo., U.S.A.) for another 2 h at

in a 1: 20 (w/w)

enzyme: BPI ratio (pH 7.5). The protein hydrolysis was stopped by heating at 75

for 20

min, then the sample was cooled down to room temperature and centrifuged for 30 min at
35,000 × g at 4

to collect the supernatant, known as the BPI hydrolysate (BPIH). The

BPIH was filtered through a 0.8 m filter, then dialyzed using 500 Da molecular weight cutoff dialysis membrane (VWR, Mississauga, ON) to eliminate salts, and lyophilized in a
LABCONCO freeze dry system. Dried BPIH was stored at -20

until further analysis

(Mojica et al., 2015).

2.2.3 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
(SDS-PAGE) analysis of the digested peptides profile
The BPI and BPIH were analyzed by SDS-PAGE to separate proteins (Oseguera-Toledo et
al., 2011). Six microliters of 5 × SDS protein sample buffer was added to 10
BPIH extract with 14
heated at 95
(24

of the BPI or

of Milli Q water in a 1.5 mL tube. Samples were vortexed and

for 5 min and centrifuged for 1 min at 25,000 × g at room temperature

). Thirty microliters of these samples were loaded on a 10% acrylamide SDS-PAGE

gel, and then the Coomassie Blue R250 was used for staining the SDS-PAGE gel to visualize
proteins and peptides (Mojica et al., 2015).

2.2.4 Determination of the quantity of digested peptides
Peptides were quantified using the PierceTM Quantitative Colorimetric Peptide Assay (#23275,
Rockford, IL. USA). This assay was modified using bicinchoninic acid (BCA) reagents with
a chelator to quantify the concentration of the peptides. The principle of this assay is the
biuret reaction or copper-based reaction, in which the amide backbone of peptides can reduce
Cu2+ to Cu+ under alkaline condition, the chelator, then, binds with Cu+ to form an orange
complex with an absorbance of 480 nm. Twenty microliters of 1000 g/mL BPIH sample
extract or peptide digest assay standards (0-1000 g/mL) were added into a 96-well plate
with 180

colorimetric peptide assay working reagent. The mixture was pre-incubated

for 30 min at 22

, then the absorbance was read with a Synergy 2 multiwell plate reader

(BioTek, Winooski, USA).
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2.2.5 Matrix Assisted Laser Desorption / Ionization-Time of
Flight/Time of Flight system (MALDI-TOF/TOF) analysis of
the digested peptides molecular mass profile
MALDI TOF/TOF was used for analyzing the molecular mass profile of common bean
BPIH at Western University MALDI Mass Spectrometry Facility, Department of
Biochemistry, to assess the molecular mass range of peptides from 600-3000 Da. Dried BPIH
samples were re-dissolved in water (0.5 g/L) and mixed with MALDI matrix (5.5 g/L
cyano 4 hydroxycinnamic acid in 6 mM ammonium phosphate monobasic, 50% acetonitrile,
0.1 % trifluoroacetic acid) at 1:1 ratio (v/v), and 0.75

of this mixture was spotted on the

MALDI plate. Mass Spectrometry data were obtained using an AB Sciex 5800 TOF/TOF
System, MALDI-TOF/TOF (Framingham, MA, USA). Data acquisition and data processing
were done using a TOF/TOF Series Explorer and Data Explorer (both from AB Sciex),
respectively. The instrument was equipped with a 349 nm Nd: YLF OptiBeam On-Axis laser.
The laser pulse rate was 400 Hz. Reflection positive mode was used and externally calibrated
at 50 ppm mass tolerance. Each mass spectrum was collected as a sum of 775 shots in the
mass to charge range from 600 to 3000 m/z. The range below 600 m/z was eliminated due to
matrix adduct peaks contamination.

2.3 Characterization of common bean bio-peptides
2.3.1 Antioxidant capacity of common bean peptides
2.3.1.1
Oxygen radical absorbance capacity (fluoresceinORAC) assay
The ORAC assay employs fluorescein (FL, EC 219-031-8, purchased from Sigma-Aldrich, St.
Louis, Mo., U.S.A.) as the fluorescent probe

-azobis (2-methylpropionamidine)

dihydrochloride (AAPH, EC 221-070-0, purchased from Cayman, Michigan, U.S.A.) as the
source of peroxyl radical, and using the difference between the area under the fluorescence
decay curve (AUC) and the natural decay curve of fluorescence as an indicator of the
antioxidant capacity of the sample. Results were expressed in units of 6-hydroxy-2, 5, 7, 8tetramethylchroman-2-carboxylic acid (Trolox, EC 258-422-8, purchased from Sigma-
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Aldrich, St. Louis, Mo., U.S.A.), a calibration standard used to quantify the antioxidant
capacity of a sample (Ou et al., 2001). Based on Dávalos et al. (2004) and Prior et al. (2003),
the ORAC assay was performed in 75 mM phosphate buffer (pH 7.4). Twenty microliters of
0.1 g/L BPIH, Trolox standards (0-

or buffer were added into a black 96-well plate
was pre-

microliters of 40 mM AAPH was added rapidly to all wells using multichannel pipettes
except the assay control (which received

), and absorbance was read

immediately with a Synergy 2 multiwell plate reader. The relative fluorescence units were
read at 485 +/- 20 nm (excitation) and 516 +/- 20 nm (emission) every minute for 90 min at
37

The ORAC-FL assay is based on the principle that the fluorescent probe is quenched

by peroxyl radicals over time by the hydrogen atom transfer process, while the oxidation of
peroxyl radicals for the fluorescent probe is blocked by antioxidants until the antioxidant
capacity in the sample is exhausted. The difference between the area under the fluorescence
decay curve of the sample and the natural decay curve of fluorescence is used as an indicator
of the antioxidant capacity of BPIH samples (Figure 2 - 1). Results were expressed as
micromoles Trolox equivalents per gram of dry BPIH extracts ( mol TE/g) (Mojica et al.,
2015).
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Figure 2 - 1: Illustration of the antioxidant capacity of the sample expressed as the net
area under the curve (Net AUC). The difference between the area under the fluorescence
decay curve of sample and the natural decay curve of fluorescence was used as an indicator
of the antioxidant capacity of samples.
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2.3.1.2

Ferric reducing/antioxidant power (FRAP) assay

The FRAP assay is used for determining the total antioxidant capacity of a sample. The
principle for this experiment is based on single electron transfer that the antioxidant can
reduce the yellow-colored ferric-tripyridyl-triazine (Fe3+-TPTZ) complex under acidic
conditions to produce a blue-colored ferric form (Fe2+-TPTZ), and then the absorbance can be
measured at 593 nm (Guo et al., 2003). The FRAP assay was done according to Khanizadeh
et al. (2008) with some modifications. Briefly, 10
Milli Q water, or standards (ascorbic acid, 62.5-1000
with 300

of BPIH sample extract (1-10 g/L),
,) were added into a 96-well plate

working FRAP reagent [prepared by mixing 300 mM acetate buffer, pH 3.6,

10 mM TPTZ (EC 222-965-9, purchased from Sigma-Aldrich, St. Louis, Mo., U.S.A.), and
20 mM FeCl3·6H2O in the ratio of 10:1:1]. The plate was incubated at room temperature for 2
h in the dark, then the absorbance read at 593 nm with a Synergy 2 multiwell plate reader.
Like the ORAC assay above, results were compared with the standard and expressed as
micromoles ascorbic acid equivalents per gram of dry BPIH extracts ( mol AAE/g).

2.3.2 DPP-IV inhibition experiment
DPP-IV inhibition was measured following the DPPIV-GloTM Protease Assay (G8351,
Promega) (Figure 2 - 2: The principle of DPP-IV inhibition experiment. The Gly-Pro
sequence in the luminogenic substrate is recognized and cleaved by the DPP-IV enzyme.
Aminoluciferin, the resulting product, is further recognized by luciferase to generate
luminescence that can be detected by a plate reader.
). This experiment was carried out in DPP-IV assay buffer (100 mM Tris-HCl, pH 8.0, 1 mM
EDTA and 200 mM NaCl) (Mojica et al., 2015). Sitagliptin (CAS 654671-78-0, purchased
from Toronto Research Chemicals, North York, ON, Canada) was used as positive control in
this experiment since it is a medication used to treat type 2 diabetes by inhibiting the DPP-IV
enzyme (Herman et al., 2005; Parmar et al., 2012).

the

buffer, BPIH (0.1-3.2 g/L) or positive control (4nM Sitagliptin)
DPP-IV human enzyme (ProSpec, East Brunswick, NJ, U.S.A.) were added into a white 96-GloTM reagent. After mixing and pre-incubation for 30 min
was measured using a Synergy 2 multiwell plate reader. Results
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were expressed as the concentration of the sample that reaches half-maximal inhibition (IC50)
of the DPP-IV enzyme as calculated using Graph Pad Prism 6.0.

Figure 2 - 2: The principle of DPP-IV inhibition experiment. The Gly-Pro sequence
in the luminogenic substrate is recognized and cleaved by the DPP-IV enzyme.
Aminoluciferin, the resulting product, is further recognized by luciferase to generate
luminescence that can be detected by a plate reader.
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2.3.3

-amylase inhibition assay

For the -amylase assay, 250

of BPIH sample extracts (0.1-1 g/L), positive control (1 mM

acarbose, EC 260-030-7; purchased from Sigma-Aldrich, St. Louis, Mo., U.S.A.), or negative
control (Milli Q water) were added into a 1.5 mL tube with 250

of 13 U/mL -amylase

[(EC 232-565-6; purchased from Sigma-Aldrich, St. Louis, Mo., U.S.A) carried out in 0.02
M sodium phosphate buffer, pH 6.9], while the blank tube was mixed with 250
sodium phosphate buffer (pH 6.9) and 2
for 10 min at 25

250

02 M

. After mixing and incubating

of 1% starch (previously dissolved in 0.02 M sodium phosphate

buffer, pH 6.9, and boiled for 15 min) was added into each tube, and tubes were incubated
again under identical conditions. Then, 500

dinitrosalicylic acid color reagent [prepared

by dissolving 1.0 g of 3,5-dinitrosalicylic acid (EC 210-204-3; purchased from SigmaAldrich, St. Louis, Mo., U.S.A.) in 50 mL of Milli Q water, then adding 30.0 g sodium
potassium tartrate tetrahydrate (EC 206-156-8; purchased from Sigma-Aldrich, St. Louis,
Mo., U.S.A.), 20 mL of 2N NaOH, and finally diluted to 100mL with Milli Q water] was
added into each tube and incubated at 100

activity. The

mixture was diluted by adding 5 mL of Milli Q water then 1.5 mL of solution was transferred
into a cuvette and the absorbance at 540 nm was determined using a BioPhotometer
(Eppendorf, Mississauga, ON). Results were expressed as percent inhibition relative to the
positive and negative control (Mojica and de Mejía, 2016).

2.3.4

-glucosidase inhibition assay

For the -glucosidase assay, 50

of BPIH sample extracts (0.1-1 g/L), positive control (1

mM acarbose), or negative control (Milli Q water) were added into a 96-well plate with 100
1 U/mL -glucosidase [(EC 3.2.1.20; purchased from Sigma-Aldrich, St. Louis, Mo.,
U.S.A.) carried out in 0.1 M sodium phosphate buffer, pH 6.9]. In contrast, the blank well
was mixed with 100

of 0.1 M sodium phosphate buffer (pH 6.9) and 50

water. After mixing and incubating for 10 min at 25

50

of Milli Q

of 5 mM p-nitrophenyl- -D-

glucopyranoside (EC 223-189-3; purchased from Millipore Sigma, St. Louis, Mo., U.S.A.)
was added into each well (dissolved in 0.1 M sodium phosphate buffer, pH 6.9) and
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incubated for another 5 min at 25

. The absorbance of the mixture was then read at 405 nm

with the Synergy 2 multiwell plate reader. Results were expressed as percent inhibition
relative to the positive and negative control (Mojica et al., 2015).

2.3.5 Lipid accumulation inhibition assay
2.3.5.1

Tissue culture and treatments

For cell culture, different quality of common bean bio-peptides were tested. BPI was prebefore pepsin/pancreatin digestion following the procedure described by MartinezVillaluenga et al. (2009). 3T3-L1 fibroblasts (ATCC® CCL-92.1TM, Manassas, VA, USA)
were seeded in a 6-well plate (6 103 cells/cm2) with Dulbecco's Modified Eagle's Medium
(DMEM) containing 10% Fetal Bovine Serum (FBS), 10 mM sodium pyruvate, 100 U/mL
streptomycin and 100 U/mL penicillin (also called FBS/DMEM medium) and grown until
reaching 100% confluence. Two days after reaching 100% confluence, fibroblast cells were
induced to differentiate to adipocytes by culturing in FBS/DMEM containing 167 nM insulin,
-isobutyl-1 methylxanthine for two days, followed by
two additional days in FBS/DMEM with 167 nM insulin. After four days of FBS/DMEM
culturing, 90% of preadipocytes were differentiated into adipocytes (as evidenced by
accumulation of fat droplets). Mature adipocytes were cultured separately with 100

BPIH

for 72 hours. All cells were cultured in VWR water-jacketed, CO2 incubator (VWR,
Mississauga, ON) at 5% CO2 and 37

conditions (Martinez-Villaluenga et al., 2009).

2.3.5.2
Lipid quantification in 3T3-L1 adipocytes by Oil Red
O assay
An Oil Red O assay was used to measure the ability of the BPIH sample to inhibit lipid
-buffered saline
(DPBS), the cultured adipocytes were fixed with 10% formalin in DPBS for 1 h, then treated
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with 60% isopropanol and dried completely. Fat droplets were stained with Oil Red O
solution (6:4 v/v with water) for 10 min, then cells were washed four times with water to
remove staining solution, followed by air-drying. Oil Red O was destained with 100%
isopropanol for 10 min, then the absorbance of the isopropanol wash was read at 510 nm
using the BioPhotometer (Martinez-Villaluenga et al., 2009).

2.3.6 Antimicrobial susceptibility test
Antimicrobial susceptibility test was performed to measure the ability of all 4 common bean
BPIH to inhibit the bacteria growth with 7 bacterial cultures: Bacillus subtilis, Erwinia
carotovora,

Escherichia

coli,

Klebsiella

pneumoniae,

Pseudomonas

aeruginosa,

Staphylococcus aureus, and Salmonella Heidelberg. Mueller Hinton agar was used in this
experiment for both bacteria growth and antimicrobial susceptibility test. Several bacteria
colonies were picked from an agar plate using a loop and transferred to 0.9% NaCl solution.
Following an adjustment of turbidity to match a 0.5 McFarland standard (1 × 108 cells/mL),
bacteria were incubated for 15 min. After that, a swab was dipped into the inoculum and
rotated against the wall of the tube above liquid to remove excess inoculum. This inoculated
swab that contained bacteria was then dispersed across the entire surface of a new sterile agar
plate three times to complete the inoculation. For the experiment, 50 mg of each dry BPIH
samples was re-suspended in 1 mL of 0.01% acetic acid and 0.2% BSA (50 mg/mL), and
spotted 5 L onto each bacteria agar plate. After allowing the BPIH samples to dry, all plates
were cultured in an ambient-air incubator (Thermo Fisher, Burlington, ON) overnight at
37

, and the condition of bacterium growth were observed and recorded. All experiment

were carried out under sterile conditions (Lalitha, 2004).

2.4 Sequence identification of the bio-active compounds
2.4.1 Pre-separation of bio-active compounds
To identify the bioactive compounds in BPIH samples that work for each experiment we
talked above, the BPIH was preliminarily separated by solid-phase extraction (SPE), which is
a convenient method for sample preparation, separation, and purification based on the
physical and chemical properties of the analytes before chromatographic analysis. After
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dialysis, the BPIH were directly loaded on to a Bond Elut Plexa SPE column (Agilent
Technologies, California, U.S.A.) without freeze drying to maximize the retention of active
compounds, then eluted with 0 to 100 % gradient of MeOH in water as a mobile phase to
separate bio-compounds which have DPP-IV inhibition and antimicrobial property. For
antioxidant capacity, an additional SPE column, C18 Cartridges (Waters, Milford, U.S.A.),
with acetonitrile (ACN) + 0.1% trifluoroacetic acid (TFA) were used as a mobile phase for
eluting. The whole process was carried out in a vacuum extraction manifold (Waters, Milford,
U.S.A.). Each time the assay was performed, a negative control (Milli Q water with pepsin
and pancreatin) was run along with the samples to ensure all active compounds for the
experiment were original from the sample solution rather than from SPE tubes, etc. The
eluted extracts were evaporated after separation to remove MeOH, then each fraction
(including negative control fraction) underwent another round of experiments to find the
active fractions for each assay. Bio-compounds in active fractions were further identified and
sequenced by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS).

2.4.2 Pronase digestion
To further confirm if the active compounds were peptides, a pronase digestion experiment
was performed before identification. Pronase is a commercially available mixture of
proteases isolated from a bacteria Streptomyces griseus, which can effectively digest proteins
into individual amino acids. Briefly, the pronase powder (EC 3.4.24.4; ~7.0 units/mg protein;
purchased from Sigma-Aldrich, St. Louis, Mo., U.S.A) was re-suspended in water and
reacted with BPIH samples (in 0.1M Tris buffer, pH 7.5) (1:10 to 1:1000 pronase: sample
ratio) (Lomenick et al., 2011). Samples were vortexed for 15 s and incubated overnight at 40
with agitation at 1400 rpm in thermomixer (Eppendorf, Mississauga, ON). Pronase digestion
was stopped by heating at 80

for 20 min, then the samples were cooled down to room

temperature and filtered through a 3K filter (Pall, Mississauga, ON) to remove pronase.
Samples after pronase digestion were tested again for the experiments discussed above. Loss
of bioactivity of the fractions indicated that the active compounds in samples were peptides.
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2.4.3 LC-MS/MS identification
The MS data were obtained using a Q-Exactive Quadrupole Orbitrap mass spectrometer
system (Thermo Fisher Scientific, Waltham, MA, U.S.A), that is coupled to an Agilent 1290
high-performance liquid chromatography (HPLC) system with a Zorbax Eclipse Plus RRHD
C18 column (2.1 x 50 mm,1.8 µm; Agilent) maintained at 35 °C. The mobile phase was
water with 0.1 % formic acid (A), and acetonitrile with 0.1 % formic acid (B) (Optima grade,
Fisher Scientific, Fair Lawn, NJ, U.S.A). Mobile phase B was held at 0 % for 0.5 min, before
being increased to 100 % over 3 min. Mobile phase B was held at 100 % for 1.5 min, before
returning to 0 % B over 0.5 min. Injections of 5 L were used with a flow rate of 0.3 mL/min.
The following conditions were used for positive HESI: capillary voltage, 4.3 kV; capillary
temperature, 400 °C; sheath gas, 25 units; auxiliary gas, 15 units; probe heater temperature,
450 °C; SLens RF level, 65. A top 5, data dependent acquisition (DDA) method was used
that involved a full MS scan at 70,000 resolution over a 150 to 1800 m/z; automatic gain
control (AGC) target and maximum injection time (max IT) were 1×106 and 256 ms
respectively. The top 5 most intense ions were selected for MS/MS at a resolution of 17,500,
AGC target and maximum injection time of 5×106 and 64 ms, respectively. The isolation
window and normalized collision energy was 1.2 m/z and 34, respectively.

2.5 Statistical Analysis
All experiments were performed in triplicate with a minimum of three biological replicates.
Data for each experiment were subjected to analysis by one-way analyses of variance
(ANOVA) using Minitab (ver. 18.1, Minitab Inc., State College, PA.), and means were
compared by Tukey honest significant difference (HSD) test
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Chapter 3: Results
3.1 Qualification and quantification for the BPIH
3.1.1 Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1
protein profiles before and after simulation of
gastrointestinal digestion
The protein profiles of the Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1 were
analyzed by SDS-PAGE of protein extract from mature seeds. Figure 3 - 1 (left) shows the
protein profiles for the different common bean varieties. Phaseolin comprises 2 to 6
polypeptides with molecular weights ranging from 43 to 54 kDa (Osborn and Brown, 1988).
Sanilac showed two major bands near 55 kDa corresponding to phaseolin. SARC1 also
showed two bands near 55 kDa that correspond to phaseolin, but less than the commercial
parent Sanilac. As expected, these bands were absent from the phaseolin-deficient lines,
SMARC1-PN1 and SMARC1N-PN1. Arcelin, a 36 kDa protein, is another seed storage
protein mostly found in wild bean varieties (Osborn et al., 1986; Taylor et al., 2008). A
prominent band showed in SARC1 and SMARC1-PN1 above 35 kDa that corresponds to the
arcelin-1, which is in accordance with the literature that introgression of the arcelin-1 allele
can lower phaseolin content (Romero-Andreas et al., 1986). This band was absent in
SMARC1N-PN1. Lectins are seed storage proteins found in common bean, with molecular
weights between 27 and 37 kDa (Sathe, 2002). Sanilac, SARC1 and SMARC1-PN1 showed
two bands correspond to lectins in a range of 25 and 35 kDa, with the band near 35 kDa
appearing prominently. These two bands were also absent in line SMARC1N-PN1. As seen
in Figure 3 - 1 (right), almost all proteins were reduced for all four varieties after pepsin and
pancreatin digestion, no bands are visible below 10 kDa.
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Figure 3 - 1: Protein profiles for different common bean varieties before and after
simulated digestion. Extracts before (undigested) and after (post pepsin/pancreatin) protease
treatment were resolved by 10% SDS-PAGE gel followed by staining with Coomassie Blue.
SAN = Sanilac; SARC = SARC1; PN1 = SMARC1-PN1; 1N-PN1 = SMARC1N-PN1.
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3.1.2 Quantification of digested peptides of the Sanilac, SARC1,
SMARC1-PN1 and SMARC1N-PN1
3.1.2.1
The molecular mass peptide profiles of the Sanilac,
SARC1, SMARC1-PN1 and SMARC1N-PN1 hydrolysates
MALDI TOF/TOF analysis was performed on the molecular mass peptides of digested
protein extracts from Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1. Table 3 - 1
shows the molecular mass profiles range from 600 to 3000 Da for the different common bean
varieties. In Sanilac BPIH, there were 56.58% peptides whose molecular mass range from
600 to 1000 Da (35.59% with 600 to 800 Da and 20.99% with 800 to 1000 Da). For SARC1
and SMARC1-PN1 BPIH, the 600 to 1000 Da peptides represented 84.21% (65.76% +
18.45%) and 82.61% (64.86% + 17.75%), respectively. SMARC1N-PN1 BPIH had 51.10%
peptides ranging from 600 to 800 Da and 18.43% from 800 to 1000 Da. The molecular mass
profiles confirmed that the proteins were digested to small peptides, and over 50% of them
ranged from 600-1000 Da for all four varieties, with the molecular mass range from 600 to
3000 Da.

Table 3 - 1: The percentage (%) of hydrolysed peptides under different molecular mass
(MM) ranges (600- 3000 Da) for all four varieties. N = 3. Values are expressed in
percentage.
MM
(Da)
range
600-800
800-1000
1000-1200
1200-1400
1400-1600
1600-1800
1800-2000
2000-3000

Sanilac
(Mean ± SD)
33.96 ± 1.49
22.57 ± 1.50
13.35 ± 1.61
7.71 ± 1.37
6.91 ± 1.23
5.75 ± 1.75
5.34 ± 0.70
4.42 ± 0.79

SARC1
(Mean ± SD)
28.16 ± 3.60
26.94 ± 2.66
17.09 ± 0.96
7.08 ± 1.94
7.59 ± 2.10
5.09 ± 2.66
4.51 ± 0.79
3.52 ± 1.32

SMARC1-PN1
(Mean ± SD)
32.59 ± 1.89
21.72 ± 1.44
19.81 ± 1.62
9.64 ± 4.79
6.81 ± 1.30
3.70 ± 0.18
4.12 ± 2.59
1.62 ± 1.97

SMARC1N-PN1
(Mean ± SD)
46.91 ± 5.94
19.53 ± 1.56
12.26 ± 3.76
7.20 ± 0.72
4.96 ± 0.05
2.80 ± 0.17
4.34 ± 0.44
1.99 ± 0.43
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3.1.2.2
Quantification of the Sanilac, SARC1, SMARC1-PN1
and SMARC1N-PN1 BPIH
Since we used alkaline extraction and acid precipitation of common bean proteins in this
project, phenolic compounds, lipids, carbohydrates, and other substances precipitated at
lower pH values could affect the purity of the proteins and ultimately concentration of the
peptides in BPIH extracts (Li et al., 2014). In this case, the quantification of the digested
Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1 peptides was analyzed by a PierceTM
Quantitative Colorimetric Peptide Assay. For Sanilac BPIH, there was 431.6 g/mL peptides
per 1 mg/mL freeze-dry BPIH extract. SARC1 had 409.4 g/mL peptides per 1000 g /mL
freeze-dry BPIH extract. SMARC1-PN1 and SMARC1N-PN1 had 436.2 g/mL and 408.6
g/mL peptides per 1 mg/mL freeze-dry BPIH extract, respectively. The quantification of
peptides for all four varieties were approximately 40 - 45% of the BPIH extracts (Table 3 - 2).
Table 3 - 2: The peptide concentration in 1 mg/mL extract for Sanilac, SARC1,
SMARC1-PN1 and SMARC1N-PN1. N = 3. Values are expressed in percentage.
Genotype

Conc. of extracts
( g /mL)

Sanilac
SARC1
SMARC1-PN1
SMARC1N-PN1

1000
1000
1000
1000

Conc. of peptides
( g /mL)
(Mean ± SD)
431.6 ± 31.84
409.4 ± 40.86
436.2 ± 22.26
408.6 ± 15.00

Percentage of peptides
(%)
43.16 ± 3.18
40.94 ± 4.09
43.62 ± 2.22
40.86 ± 1.50
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3.2 Assessment of the predicted bioactivity for the BPIH
3.2.1
Inhibitors for

-a
-a

-glucosidase enzymes
-glucosidase enzymes are

because they inhibit those enzymes which can break down starch into glucose, thereby
lowering post-meal blood glucose levels (Zhang et al., 2020). Acarbose is a known
pharmaceutical inhibitor of -amylase and -glucosidase, and is used as positive control (100%
inhibition) in experiments for calculating the percentage inhibition of these two enzymes.
(Mojica et al., 2015). Table 3 - 3 revealed that the percentage inhibition of Sanilac BPIH for
-amylase was relatively low (lower than 6% inhibition compared with acarbose). Moreover,
despite the increase in BPIH concentration, there was no increase in -amylase inhibition as
expected.

Table 3 - 3: Effect of different Sanilac BPIH concentration on
inhibition. N = 3. Values are expressed in percentage.
Samples
0.5 mg/mL Sanilac BPIH
1 mg/mL Sanilac BPIH
2 mg/mL Sanilac BPIH
5 mg/mL Sanilac BPIH
10 mg/mL Sanilac BPIH
1mM acarbose

-amylase inhibition (%)
(Mean ± SD)
5.74 ± 2.08
4.59 ± 1.11
4.20 ± 1.67
5.12 ± 1.57
2.25 ± 1.49
100 ± 0.75

-amylase enzyme
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The Sanilac BPIH made with different cooking time of mature seeds were also measured for
-amylase inhibition experiment to test if cooking times impacted enzyme inhibition
properties of BPIH. Sanilac seeds, boiled for 15 min, 30 min and 1 h, were used for making
the BPIH, followed by enzyme inhibition assays. The result indicated that different cooking
time had little to no effect on the property of Sanilac BPIH to inhibit -amylase enzyme
(Table 3 - 4).

Table 3 - 4: Effect of different Sanilac BPIH cooking time (15 min, 30 min, 60 min) on
-amylase enzyme inhibition. N = 3. Values are expressed in percentage.
Samples
Sanilac BPIH cook for 15 min
Sanilac BPIH cook for 30 min
Sanilac BPIH cook for 60 min
1mM acarbose

-amylase inhibition (%)
(Mean ± SD)
5.99 ± 5.77
5.62 ± 3.51
4.79 ± 3.87
100 ± 0.45
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The percentage inhibition of 0.1 mg/mL Sanilac, SARC1, SMARC1-PN1 and SMARC1NPN1 BPIH of -amylase enzyme are shown in Table 3 - 5. The data corresponded to average
percentage inhibition of three technical replicates. It was clear that there was no significant
-amylase among four common bean varieties (P > 0.05), and
none of the common bean peptides had more than 10% inhibition of -amylase enzyme
activity.

Table 3 - 5: Effect of 0.1 mg/mL of four genotypes BPIH (Sanilac, SARC1, SMARC1PN1, and SMARC1N-PN1) on -amylase enzyme inhibition. Values are expressed in
percentage; n =3. P =0.794.
Samples
0.1 mg/mL Sanilac BPIH
0.1 mg/mL SARC1 BPIH
0.1 mg/mL SMARC1-PN1 BPIH
0.1 mg/mL SMARC1N-PN1 BPIH
1mM acarbose

-amylase inhibition (%)
(Mean ± SD)
7.13 4.94
8.78 ± 3.65
5.08 ± 4.59
8.48 ± 7.78
100 ± 1.22

30

The percentage inhibition of -glucosidase enzyme for all four cultivars are presented in
Figure 3 - 2. They correspond to average percentage inhibition of three technical replicates.
T

-glucosidase was relatively low, and none of the common bean varieties

among the concentrations of BPIH from 0.1 to 1 mg/mL had any significant (P > 0.05)
inhibition, as well as interaction of cultivars and their BPIH concentration. All samples
ranged between 0 and 10% inhibition.

-Glucosidase %inhibition

80%
70%
60%
50%
40%
30%
20%
10%
0%
Sanilac

SARC1

PN1

1N-PN1

Common bean cultivars
0.1mg/mL BPIH

0.5mg/mL BPIH

1mg/mL BPIH

Figure 3 - 2:
-Glucosidase enzyme response to 0.1 mg/mL Sanilac, SARC1,
SMARC1-PN1 and SMARC1N-PN1 BPIH. Values are expressed in percentage; n =3.

Thus, common bean protein hydrolysates with the potential to inhibit

-a

-

glucosidase were not been detected in this project. The average percentage inhibition of
theses two enzymes by four common bean cultivars with different BPIH were all less than
10%. As such, no further research was performed for this area of my project.

31

3.2.2 The 3T3-L1 tissue culture
Obesity is one of the risk factors for type 2 diabetes, and the prevalence of diabetes increases
significantly among chronically obese people (Al-Goblan et al., 2014). The 3T3-L1 cell line
was derived from mouse embryos, and is a fibroblast-like cell line used to study adipose
metabolism (Martinez-Villaluenga et al., 2009). Figure 3 - 3 (left) shows how 3T3-L1
fibroblasts and mature adipocytes look like, and Figure 3 - 3 (right) demonstrates how lipid
droplets appear after staining with Oil Red.
pre-adipocytes (fibroblast)

lipid droplets stained with Oil Red

adipocytes

lipid droplets

Figure 3 - 3: Pre-adipocytes and mature adipocytes under phase contrast microscope
(left) and lipid droplets stained with Oil Red under microscope (right).
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Unexpectedly, the inhibition of lipid droplets accumulation was not seen in the mature 3T3L1 cell line treated with Sanilac and SMARC1N-PN1 BPIH based on the Oil Red O assay.
The absorbance for untreated and treated cell cultures was at the same level (around 0.9)
(Figure 3 - 4), thus indicating that common bean protein hydrolysates do not inhibit lipid
growth in culture. Therefore, no further research was performed in this area of my project.

1
0.9

0.899

0.905

0.897

Sanilac

SMARC1N-PN1

Absorbance 510 nm

0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Untreated

Figure 3 - 4: Absorbance of untreated and treated 3T3-L1 cell cultures with Sanilac and
SMARC1N-PN1 BPIH. Values are the absorbance at 510 nm. N = 3.
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3.2.3 Antioxidant capacity
3.2.3.1
Oxygen radical absorbance capacity (fluoresceinORAC) assay
The ORAC-FL assay is based on a hydrogen atom transfer reaction, related to radical chainbreaking capacity of antioxidants (Prior, 2015). The unit of ORAC value was expressed as
micromoles Trolox equivalents per gram of dry BPIH extracts ( mol TE/g). Data in Table 3 6 revealed that 0.1 mg/mL dry BPIH extract from SMARC1N-PN1 had the significantly
highest antioxidant capacity (P < 0.05) among the four cooked bean varieties (up to 362.73
dry BPIH extract), followed by SARC1, SMARC1-PN1, and Sanilac. The
difference in ORAC value between SMARC1-PN1 and SARC1 was not significant (P >
0.05); the same was true between SMARC1-PN1 and Sanilac.

Table 3 - 6: The Net AUC corresponding to the different varieties of common bean and
the calculated Trolox equivalents concentration and ORAC value, n=6.
Variety

Sanilac
SARC1
SMARC1-PN1
SMARC1N-PN1

Dry BPIH
Conc.
(mg/mL)
0.1
0.1
0.1
0.1

Net AUC
(Mean ± SD)
19.87 ± 1.61
22.33 ± 0.91
21.66 ± 1.59
26.02 ± 1.25

Trolox
Equivalents Conc.
( mol/L)
(Mean ± SD)
25.91 ± 2.45
29.94 ± 1.10
28.79 ± 2.60
36.27 ± 1.68

ORACFL ( mol
TE/g)
(Mean ± SD)
259.10 ± 24.50 c
299.42 ± 10.95 b
287.87 ± 26.00 bc
362.73 16.81 a

Means followed by the same letter within columns are not significantly different according to T-protected HSD
test at
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3.2.3.2

Ferric reducing/antioxidant power (FRAP) assay

The FRAP assay is based on single electron transfer reaction, related to the capacity of
antioxidants to reduce an oxidant, concomitantly with a color change (Huang et al., 2005).
The unit of FRAP value was expressed as micromoles ascorbic acid equivalents per gram of
dry BPIH extracts (

AAE/g). The 30 mg/mL dry BPIH extract from SARC1 BPIH

recorded the highest FRAP value (up to 6.91

AAE/g dry BPIH extract), followed by

Sanilac, SMARC1-PN1 and SMARC1N-PN1. The difference in FRAP value between
SARC1 and Sanilac was not significant (P > 0.05); however, the FRAP value decreased
significantly (P<0.05) in SMARC1-PN1 and SMARC1N-PN1 (Table 3 - 7).

Table 3 - 7: The calculated ascorbic acid equivalents concentration and FRAP value,
n=3.
Variety

Sanilac
SARC1
SMARC1-PN1
SMARC1N-PN1

Conc. (mg/mL)

30
30
30
30

Ascorbic acid
Equivalents Conc.
(Mean ± SD)
195.26 ± 0.23
207.22 ± 1.38
177.99 ± 2.52
162.49 ± 9.02

AAE/g)
(Mean ± SD)
6.51 ± 0.23 a
6.91 ± 0.05 a
5.93 ± 0.08 b
5.42 ± 0.30 c

Means followed by the same letter within columns are not significantly different according to T-protected HSD
test at
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3.2.4 DPP-IV inhibition activity
The IC50 value indicates the half-inhibition concentration, which refers to the drug or
inhibitor concentration required to inhibit half of a specific biological or biochemical process
(Swinney, 2011). For the DPP-IV inhibition experiment, the lower the IC50 value, the
stronger the inhibition property of the common bean derived BPIH. Figure 3 - 6 indicates
that SMARC1N-PN1 BPIH had the lowest IC50 value among the four varieties (0.86 mg/mL
freeze-dry BPIH extract), which means it had the strongest potential to block the DPP-IV
enzyme, followed by Sanilac, SMARC1-PN1, and SARC1.

Sanilac

SARC1

SMARC1-PN1

SMARC1N-PN1

Figure 3 - 5: IC50 curves corresponding to the different varieties of common bean BPIH
which represent different DPP-IV inhibition abilities.
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3.2.5 Antimicrobial ability
After overnight incubation, the status of bacterium growth was observed and recorded. The
circular area in each plate means zone of inhibition where bacteria can not grow. Larger area
and darker color of zone of inhibition represents for the better antimicrobial capability of the
samples. Figure 3 - 6 indicates that the BPIH for all four varieties possessed antimicrobial
activity against B. subtilis and S. aureus, some activity against E. coli and K.
pneumoniaaureus, little to no activity against P. aeruginosa, and no activity against E.
carotovora and S. heidelberg. Gram-positive bacteria, B. subtilis and S. aureus, appear to be
sensitive to killing.

Bacillus subtilis

Staphylococcus aureus

Escherichia coli

Klebsiella pneumoniae

Pseudomonas aeruginosa

Erwinia carotovora

Salmonella heidelberg
Figure 3 - 6: Antimicrobial susceptibility test results for all common bean BPIH with 7
bacterial cultures. Bacterial cultures including Bacillus subtilis, Staphylococcus aureus,
Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Erwinia carotovora, and
Salmonella Heidelberg. 1 = Sanilac; 2 = SMARC1-PN1; 3 = SARC1; 4 = SMARC1N-PN1;
5 = negative control.
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3.3 Bioactive compounds identification
3.3.1 Bioactive compounds identification for DPP-IV inhibition
3.3.1.1
DPP-IV inhibition by solid-phase extraction (SPE)
fractions
Since it had the highest DPP-IV inhibition property (Figure 3 - 5), the SMARC1N-PN1
BPIH was used for testing whether the active compounds would elute using MeOH from
Bond Elut Plexa SPE columns. Figure 3 - 7 confirmed that almost all active compounds in
SMARC1N-PN1 BPIH, which exhibited DPP-IV enzyme inhibition activity, were eluted by
100% MeOH.

80%

DPP-IV enzyme %inhibition

70%

69.01%
61.13%

60%
50%
40%
30%
20%
10%

4.95%

-0.62%

0%
-10%

SMARC1N-PN1
BPIH

Flow-through

0% MeOH

100% MeOH

Fractions

Figure 3 - 7: The DPP-IV inhibitory activity of SMARC1N-PN1 BPIH and its fractions
that eluted by 0% and 100% MeOH. BPIH was loaded into Bond Elut Plexa SPE column,
n=3. Flow-through = flow-through from the SPE column; 0% MeOH = solution with
compounds eluted by 0% MeOH; 100% MeOH = solution with compounds eluted by 100%
MeOH.
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The SMARC1N-PN1 BPIH loaded into a SPE column was then eluted by increasing
concentrations of MeOH with 25% interval from 0% to 100%. Data in Figure 3 - 8 indicate
that almost all active compounds in SMARC1N-PN1 BPIH which have inhibitory effect on
DPP-IV enzyme were eluted by 75% MeOH, which means the active compounds were
located between the 50% and 75% MeOH fraction.

DPP-IV enzyme %inhibition

110%
85.87%

90%
74.34%
70%
50%
30%
10%

6.58%

-5.09%

-3.05%

-2.24%

-0.90%

-10%

SMARC1N-PN1 Fractions

Figure 3 - 8: The DPP-IV inhibition results for SMARC1N-PN1 BPIH and its fractions
that eluted by 0% to 100% MeOH with 25% interval. BPIH was loaded into Bond Elut
Plexa SPE column, n=3. Flow-through = flow-through from the SPE column; 0% MeOH =
solution with compounds eluted by water; 25-100% MeOH = solution with compounds
eluted by 25-100% MeOH.
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The SMARC1N-PN1 BPIH was further eluted from SPE column by MeOH, with 10%
interval between 50% to 80%, and 100% MeOH. Data in Figure 3 - 9 indicate that the
majority of active compounds in SMARC1N-PN1 BPIH which have inhibitory effect on
DPP-IV enzyme were eluted by 70% MeOH, which means the active compounds were
located between the 60% and 70% MeOH fraction. Active compounds that could inhibit
DPP-IV enzyme were also found in 80% MeOH fraction. Previous results showed that the
active compounds were located between the 50% and 75% MeOH fraction (Figure 3 - 8),
revealing that the active compounds are eluted between 60 to 75% MeOH fraction.

DPP-IV enzyme %inhibition

80%
70%
60%

66.23%
57.42%

50%
40%
30%

14.65%

20%
10%
0%

2.12%

-2.50%

-5.11%

-5.30%

-4.40%

-10%
-20%

SMARC1N-PN1 Fractions

Figure 3 - 9: The DPP-IV inhibition results for SMARC1N-PN1 BPIH and its fractions
that eluted by 0%, 50%, 60%, 70%, 80, and 100% MeOH. BPIH was loaded into Bond
Elut Plexa SPE column, n=3. Flow-through = flow-through from the SPE column; 0% MeOH
= solution with compounds eluted by water; 50-100% MeOH = solution with compounds
eluted by 50-100% MeOH.
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The negative control was water containing the same concentration of pepsin and pancreatin
as BPIH samples and incubated under the identical conditions. The inhibitory effect of
negative control solution loaded into a Bond Elut Plexa SPE column and eluted by different
concentrations of MeOH on DPP-IV enzyme is shown in Figure 3 - 10. The results
confirmed that all active compounds for the DPP-IV inhibition experiment were originally
from the SMARC1N-PN1 BPIH solution rather than from the SPE column, pepsin and
pancreatin, or liquids used for elution, etc.

DPP-IV enzyme %inhibition

100%
80%
60%
40%
20%
0%

-5.39%

-0.59%

0.52%

-3.74%

-2.96%

-3.37%

-4.08%

-3.49%

-20%

Negative control fractions

Figure 3 - 10: The DPP-IV inhibition results for negative control and its fractions that
eluted by 0%, 50%, 60%, 70%, 80, and 100% MeOH. Negative control was loaded into
Bond Elut Plexa SPE column and n=3. Flow-through = flow-through from the SPE column; 0%
MeOH = solution with compounds eluted by water; 50-100% MeOH = solution with
compounds eluted by 50-100% MeOH.
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The BPIH of Sanilac, SARC1, and SMARC1-PN1 and SMARC1N-PN1 were then SPE
fractionated at the same time under the identical environment and this confirmed that, like the
results of SMARC1N-PN1 shown in Figure 3 - 7 and Figure 3 - 8, the majority of active
compounds were in 50

75% MeOH for all varieties. The BPIH of four varieties were

further eluted by 0% MeOH, 10% interval between 50% to 80% MeOH, and 100% MeOH.
Figure 3 - 11 shows that the majority of active compounds in BPIH of all four cultivars,
exhibiting DPP-IV inhibition activity, were eluted by 80% MeOH, which means the active
compounds were located between the 70% and 80% MeOH fraction. SPE is a pre-separated
method of active compounds, which means it is a rough separation of active compounds
compare with other accurate separation methods like HPLC. The result in Figure 3 - 11
shows a little bit different elution pattern for SMARC1N-PN1 than in Figure 3 - 8 and
Figure 3 - 9 (active compounds for SMARC1N-PN1 were located between the 60% and 75%
MeOH fraction), which possibly due to the instrument error. Based on above mentioned three
figures, the active compounds should be eluted near the 70% MeOH fraction.

70%
60%

DPP-IV %inhibition

50%
40%
30%
20%
10%
0%
-10%

Fractions for different common bean cultivars
sanilac

sarc1

pn1

1N-PN1

Figure 3 - 11: The DPP-IV inhibition results for Sanilac, SARC1, SMARC1-PN1,
SMARC1N-PN1 BPIH, and their fractions that eluted by 0%, 50%, 60%, 70%, 80, and
100% MeOH. BPIH were loaded into Bond Elut Plexa SPE column, n=3. Flow-through =
flow-through from the SPE column; 0% MeOH = solution with compounds eluted by water;
50-100% MeOH = solution with compounds eluted by 50-100% MeOH.
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The peptide quantification of each fraction for all four common bean cultivars was tested and
presented in Table 3 - 8. The data demonstrated that most peptides remained in the flowthrough solution, and the eluted peptides were detected in the lower %MeOH fractions (0%
and 50% MeOH fractions), but not in the fractions containing active compounds which
inhibit DPP-IV enzyme activity (70% and 80% MeOH fractions). Based on these findings, it
unlikely that the active compounds are peptides.

Table 3 - 8: The peptide concentration
SMARC1N-PN1 BPIH, and their fractions; n=3.
BPIH
(Mean ±
SD)

-PN1,

Sanilac

5116.0
70.0

Flowthrough
(Mean ±
SD)
3667.8 ±
76. 1

0%
MeOH
(Mean ±
SD)
671.9 ±

50%
MeOH
(Mean ±
SD)
190.8 ±

60%
MeOH
(Mean
± SD)
14.0 ±

70%
MeOH
(Mean
± SD)

80%
MeOH
(Mean
± SD)

100%
MeOH
(Mean
± SD)

14.6

8.1

2.6

<9.1

<9.1

<9.1

SARC1

3450.2 ±
109.7

2236.6 ±
135.0

308.4 ±
10.4

217.5 ±
6.2

55.7 ±
5.4

20.8 ±
1.5

<5.9

<5.9

SMARC1PN1

3392.2 ±
61.6

2729.2 ±
31.0

279.0 ±
7.0

272.0 ±
2.6

15.2 ±
7.4

10.2 ±
6.4

<5.9

<5.9

SMARC1N
-PN1

3724.6 ±
83.5

2125.8 ±
48.2

375.1 ±
3.2

224.4 ±
5.7

25.2 ±
5.9

12 ±
6.6

<5.7

<5.7
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3.3.1.2

Pronase digestion of common bean BPIH

To further determine if the active compounds which inhibited DPP-IV enzyme were peptides,
Pronase was used to digest the BPIH of four common bean cultivars before identification.
Based on Lomenick et al. (2011), Pronase is composed of highly reactive enzymes that can
digest almost all proteins completely within the Pronase-protein ratio range of 1: 100 to 1:
10,000. Figure 3 - 12 depicts the result for the DPP-IV inhibition assay of Sanilac BPIH
itself and with Pronase added at ratios from 1:10 to 1:1000. Interestingly, regardless of how
much Pronase was added, the ability of Sanilac BPIH to block DPP-IV enzyme activity
remained at a similar level.

100%
90%

DPP-IV inhibition

80%
70%

58.40% 58.59% 58.85%

60%

54.59% 58.00% 56.44% 60.65%

50%
40%
30%
20%
10%
0%
BPIH

1:10

1:50

1:100

1:200

1:500

1:1000

pronase:sample ratio

Figure 3 - 12: DPP-IV inhibition results for Sanilac BPIH itself and after treatment with
Pronase at ratios ranging from 1: 10 to 1:1000, n= 3.

44

BPIH from all four cultivars were also treated with Pronase at ratio 1: 500. DPP-IV inhibition
results are presented in Figure 3 - 13 indicating that BPIH-mediated DPP-IV inhibition was
still detectable after Pronase digestion. These findings further confirm that the active
compounds were probably not peptides.

100%

DPP-IV %Iinhibition

90%
80%
70%

61.13%

60%

66.65%
55.16%

53.87%

SARC1

SMARC1-PN1

50%
40%
30%
20%
10%
0%
Sanilac

SMARC1N-PN1

Pronase: BPIH ratio = 1:500

Figure 3 - 13: The DPP-IV inhibition results for Sanilac, SARC1, SMARC1-PN1 and
SMARC1N-PN1 BPIH after treatment with Pronase at a ratio of 1: 500, n= 3.
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3.3.1.3
Identification and putative chemical formula of active
compounds that inhibit DPP-IV enzyme by LC-MS/MS
Since the cultivar extracts showed a similar pattern of elution (Figure 3 - 11), and
SMARC1N-PN1 had the highest DPP-IV inhibition property (Figure 3 - 5), this cultivar was
chosen to identify the active compounds that inhibit DPP-IV enzyme. The HPLC results
demonstrated that 1223 compounds in total were found in SMARC1N-PN1 BPIH but 821
were removed because they did not appear in any of the fractions analyzed. It is possible that
some compounds either remained in the flow-through solution, did not survive the dry down
step, or remained bound to the SPE column. Since the SMARC1N-PN1 BPIH was much
more complex than an individual fraction, some compounds might have been observed in a
fraction but may be below the limit of detection or at low levels in the SMARC1N-PN1 BPIH,
so they were retained. The rest of the 402 compounds were analysed with 42 compounds
exhibiting maximum peak areas in the 70% and 80% MeOH fractions, and 32 of them were
only presenting in these two fractions, highlighted in yellow (Table 3 - 9).
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Table 3 - 9: Compounds with maximum peak areas in 70% and 80% MeOH fraction.
Compounds highlighted in yellow were only present in 70% and 80% MeOH. Features are
arranged by the size of peak area from top to bottom.
Row
ID

m/z

RT (min)

Crude (-)

Crude (+)

50 (+)

60 (+)

70 (+)

80 (+)

100 (+)

1

594.4479

4.73

0

0

0

0

6.00E+09

0

0

2

566.4178

4.94

0

0

0

0

5.66E+09

0

0

3

780.5521

4.89

0

0

0

0

5.47E+09

0

0

4

524.3718

5.06

0

1.61E+10

0

2.19E+09

3.61E+09

0

0

5

567.4227

4.94

0

0

0

0

2.60E+09

0

0

6

588.4008

5.18

0

0

0

0

1.94E+09

0

0

7

781.5562

4.89

0

0

0

0

1.73E+09

0

0

8

595.4525

4.49

0

0

0

0

1.57E+09

0

0

9

802.5333

5.19

0

0

0

0

1.25E+09

0

0

10

616.4301

5.19

0

0

0

0

7.20E+08

0

0

11

803.5369

5.19

0

0

0

0

6.17E+08

0

0

12

546.3523

5.19

0

3.15E+09

0

1.48E+08

6.11E+08

0

0

13

525.3755

5.05

0

4.15E+09

0

1.50E+08

4.36E+08

0

0

14

582.3757

4.44

0

0

0

0

3.39E+08

0

0

15

907.5774

4.5

0

1.21E+09

9.91E+07

2.68E+08

3.14E+08

0

0

16

782.562

4.89

0

0

0

0

2.91E+08

0

0

17

313.2739

4.51

0

0

0

0

2.44E+08

0

0

18

754.5376

4.73

0

0

0

0

2.33E+08

0

0

19

596.4564

4.73

0

0

0

0

2.32E+08

0

0

20

617.433

5.18

0

0

0

0

2.04E+08

0

0

21

547.3561

5.19

0

8.02E+08

0

0

1.61E+08

0

0

22

482.3241

4.97

0

0

0

0

1.48E+08

0

0

23

545.3394

4.66

0

0

0

1.33E+08

1.41E+08

0

0

24

485.2867

4.07

0

0

0

0

1.40E+08

0

0

25

908.5829

4.5

0

5.45E+08

0

1.21E+08

1.27E+08

0

0

26

502.29

4.62

0

0

0

0

1.08E+08

0

0

27

456.2991

4.5

0

2.97E+08

4.08E+07

7.09E+07

9.13E+07

0

0

28

526.3766

5.08

0

0

0

0

5.18E+07

0

0

29

1115.7997

4.64

0

0

0

0

5.17E+07

0

0

30

755.5411

4.73

0

0

0

0

4.75E+07

0

0

31

1089.7852

4.58

0

0

0

0

4.35E+07

0

0

32

436.2827

4.51

0

9.80E+07

0

0

3.78E+07

0

0

33

1019.701

4.51

0

0

0

0

3.49E+07

0

0

34

1116.7996

4.64

0

0

0

0

3.25E+07

0

0

35

399.2522

4.8

1.52E+09

0

0

0

3.11E+07

0

2.93E+07

36

483.328

4.97

0

0

0

0

2.54E+07

0

0

37

353.2686

4.99

0

3.23E+08

0

0

2.29E+07

0

0

38

1090.7841

4.58

0

0

0

0

2.00E+07

0

0

39

804.5453

5.19

0

0

0

0

2.87E+07

2.75E+09

0

40

596.3909

4.54

0

0

0

0

0

1.65E+09

0

41

230.2477

3.92

0

0

0

0

0

7.57E+07

0

42

200.2371

3.86

0

0

0

0

0

6.02E+07

0
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According to the LC-MS/MS analysis, the active compounds in 70% and 80% MeOH
fractions that blocked the DPP-IV enzyme were identified as lipid compounds. There were 32
compounds identified in total, while 2 of them were considered as contaminants (Row ID 28
and 35) by the chemist Dr. Justin Renaud based on the criteria that they were either detected
in the negative control [Crude (-)] or as an isotope of other compounds which detected in the
Crude (-). There were 8 of 32 compounds indicated as potential active compounds that inhibit
DPP-IV

enzyme

belonging

to

lipid

classes:

monoacylglycerol

(MG),

phosphatidylethanolamine (PE), phosphatidylglycerol (PG) and 5 phosphatidylcholines (PC).
The putative chemical formula and possible structure for these 8 compounds are reported in
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Table 3 - 10. The phosphatidylcholines seem more abundant than other lipid compounds
based on peak intensity in Table 3 - 9 (Row ID 1, 2, 3, 14, 18), and the monoacylglycerol
may be potentially important because it was only detected in the 70% MeOH fraction and
BPIH solution. There were 2 additional compounds belonging to phosphatidylcholine based
on MS/MS fragmentation, but the formula could not be identified. Others represented either
the isotope or sodiated form of these compounds. With Mass Spec alone, it is hard to identify
the structure for any of these compounds accurately. In future studies, it would be of interest
to perform nuclear magnetic resonance to identify these potential active compounds, then
obtain them from a commercial manufacturer or isolate and purify from common bean BPIH,
and test for the DPP-IV inhibition individually.
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Table 3 - 10: The putative formula and possible structure of active compounds derived
from SMARC1N-PN1 that might inhibit the DPP-IV enzyme.
Putative
formula
C21H36O4
Monoacylglycerol
MG
(0:0/18:3/0:0)
MW: 353.27
RT: 5.00
Row ID: 37

Possible structure

Putative formula
C23H48NO7P
Phosphatidylethanolamine
PE (18:0/0:0)
MW: 482.32
RT: 4.97
Row ID: 22

C22H45O9P
Phosphatidylglycerol
PG (16:0/0:0)
MW: 485.29
RT: 4.07
Row ID: 24

C29H60NO7P
Phosphatidylcholine
MW: 566.42
RT: 4.94
Row ID: 2

C29H60NO8P
Phosphatidylcholine
MW: 582.38
RT: 4.44
Row ID: 14

C31H64NO7P
Phosphatidylcholine
MW: 594.45
RT: 4.73
Row ID: 1

C42H76NO8P
Phosphatidylcholine
MW: 754.54
RT: 4.73
Row ID: 18

C44H78NO8P
Phosphatidylcholine
MW: 780.56
RT:4.89
Row ID: 3

Possible structure
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3.3.2 Solid-phase extraction
antimicrobial property

(SPE)

fraction

action

for

According to Figure 3 - 6, the antimicrobial capacity of BPIHs derived from the four
cultivars, B. subtilis exhibited the highest susceptibility compared to the other 6 bacteria, so it
was the only one chosen for the active compounds identification. The steps of SPE
fractionation for the separation of the antimicrobial active compounds in BPIH were the same
as those for the separation of active compounds inhibiting DPP-IV enzyme. Sanilac, SARC1,
SMARC1-PN1 and SMARC1N-PN1 BPIH were flowed through the Bond Elut Plexa SPE
column and eluted by 0% and 100% MeOH. The result is presented in Figure 3 - 14. Most
active compounds in Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1 BPIH which had
antimicrobial properties were eluted by 100% MeOH, while there were still some active
compounds that remained in the flow-through solution.

B.subtilis affected by BPIH (4 cultivars)

B.subtilis affected by flow-through solution (4
cultivars)

B.subtilis affected by 0% MeOH (4 cultivars)

B.subtilis affected by 100% MeOH (4 cultivars)

Figure 3 - 14: Antimicrobial susceptibility test result for Sanilac, SARC1, SMARC1PN1, SMARC1N-PN1 BPIH, and their SPE fractions to inhibit B. subtilis. 1 = Sanilac; 2
= SARC1; 3 = SMARC1-PN1; 4 = SMARC1N-PN1; 5 = Positive control (Penicillin); 6 =
negative control.
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The peptide quantification of each fraction for all four common bean cultivars was also tested
and presented in Table 3 - 11. The data demonstrated that most peptides remained in the
flow-through solution, but not in the fractions containing active compounds which had
antimicrobial property (100% MeOH fractions). These findings indicate that the
antimicrobial active compounds were also probably not peptides.

Table 3 - 11:
SMARC1-PN1 and SMARC1N-PN1 BPIH and their fractions. n=3.

Sanilac
SARC1
SMARC1-PN1
SMARC1N-PN1

BPIH (Mean ± SD)
4850.0 ± 558.0
4338.0 ± 174.9
4667.1 ± 38.0
5923.5 ± 203.6

Flow-through
(Mean ± SD)
4720 ± 30.0
3891 ± 35.0
4218 ± 33.9
4588 ± 78.2

0% MeOH
(Mean ± SD)
471.5 ± 23.18
433.34 ± 10.2
459.93 ± 20.0
408.2 ± 8.1

100%MeOH
(Mean ± SD)
208.1 ± 6.1
206.66 ±24.2
226.9 ± 11.3
484.8 ± 29.0

The Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1 BPIH were then loaded onto the
Bond Elut Plexa SPE column and eluted by MeOH with 0% to 100% in 25% increments.
Figure 3 - 15 indicated that active compounds which had some antimicrobial properties were
found in in plates treated with 50, 75 and 100% MeOH fraction, whereas plates treated with 0%
and 25% MeOH fractions exhibited no antimicrobial effects. The results suggested that active
compounds could not be well-separated by MeOH in this case.
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B.subtilis affected by BPIH (4
varieties)

B.subtilis affected by flow-through
solution (4 varieties)

B.subtilis affected by 0% MeOH (4
varieties)

B.subtilis affected by 25% MeOH
(4 varieties)

B.subtilis affected by 50%
MeOH (4 varieties)

B.subtilis affected by 75%
MeOH (4 varieties)

B.subtilis affected by 100%
MeOH (4 varieties)

Figure 3 - 15: Antimicrobial susceptibility test result for Sanilac, SARC1, SMARC1PN1, SMARC1N-PN1 BPIH, and their fractions that eluted with 0% MeOH to 100%
MeOH at 25% increments to inhibit B. subtilis. BPIH were loaded into Bond Elut Plexa
SPE column. 1 = Sanilac; 2 = SARC1; 3 = SMARC1-PN1; 4 = SMARC1N-PN1; 5 =
negative control; 6 = Positive control (Penicillin).
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3.3.3 Solid-phase extraction (SPE) fraction action for antioxidant
capacity
Although the results of different antioxidant experiments cannot be compared since the
different methods involved different chemistries ((Huang et al., 2005; Prior, 2015), it was
clear that the experimental principle for the ORAC assay were more similar to how human
body detoxify ROS than those of FRAP assay. Moreover, the FRAP values were relatively
low, which means that the color change was not easily observed (Table 3 - 6 and Table 3 - 7).
So, the ORAC assay was the one chosen for further active compounds identification.
According to Table 3 - 6, the SMARC1N-PN1 BPIH exhibited the highest antioxidant
capacity, so this cultivar was further assessed to determine if the active compounds would
elute by 0% and 100% MeOH following SPE fractionation with Bond Elut Plexa SPE column.
However, the results suggested that most active compounds in SMARC1N-PN1 BPIH with
antioxidant capacity remained in the flow-through solution (Table 3 - 12).

Table 3 - 12: The Net AUC and Trolox equivalents concentration corresponding to the
SMARC1N-PN1 BPIH and its fractions that eluted with 0% and 100% MeOH. BPIH
was loaded onto Bond Elut Plexa SPE column; n=3.
Fractions
SMARC1N-PN1 BPIH
Flow-through
0% MeOH
100% MeOH

Net AUC
(Mean ± SD)
46.63 ± 1.71
35.05 ± 1.05
6.80 ± 0.57
14.01 ± 0.97

Trolox Equivalents Conc. ( mol/L)
(Mean ± SD)
88.71 ± 3.45
65.28 ± 2.49
0.14 ± 1.32
16.76 ± 0.53
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The negative control consisted of water containing the same concentration of pepsin and
pancreatin as the BPIH samples and incubated under identical conditions. The antioxidant
capacity of the negative control loaded into Bond Elut Plexa SPE column and eluted by
different concentrations of MeOH is shown in Table 3 - 13. The result confirmed that all
active compounds for the antioxidant experiment originated from the SMARC1N-PN1 BPIH
solution rather than from the SPE column, pepsin and pancreatin, etc.

Table 3 - 13: The Net AUC and Trolox equivalents concentration corresponding to the
negative control and its fractions that eluted with 0% and 100% MeOH. BPIH was
loaded into Bond Elut Plexa SPE column, n = 3.
Fractions
Negative control
Flow-through
0% MeOH
100% MeOH

Net AUC
(Mean ± SD)
9.82 ± 1.14
5.90 ± 0.53
2.70 ± 1.39
0.63 ± 0.12

Trolox Equivalents Conc. ( mol/L)
(Mean ± SD)
12.17 ± 2.23
6.34 ± 0.78
1.58 ± 0.63
<1.16
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In order to separate the active antioxidant compounds of SMARC1N-PN1 BPIH that
remained in the flow-through solution, an additional C18 SPE column, which is specific for
peptide separation was used. The previously collected solution flowing through the Bond Elut
Plexa SPE column was loaded again into the C18 column and eluted with ACN + 0.1% TFA
instead of MeOH. Table 3 - 14 revealed that active antioxidant compounds in SMARC1NPN1 BPIH which were loaded into the Bond Elut Plexa SPE column but remained in the
flow-through solution were eluted and separated by the C18 column with 0% and 100% ACN
+ 0.1%TFA.

Table 3 - 14: The Net AUC and Trolox equivalents concentration corresponding to the
SMARC1N-PN1 BPIH and its fractions; n = 3.
Fractions
SMARC1N-PN1 BPIH
Bond Elut Plexa flow-through
C18 flow-through
0% ACN + 0.1%TFA
100% ACN + 0.1%TFA

Net AUC
(Mean ± SD)
48.09 ± 0.77
31.76 ± 1.60
6.75 ± 0.98
12.09 ± 0.03
13.63 ± 0.46

Trolox Equivalents Conc. ( mol/L)
(Mean ± SD)
87.01 ±1.50
55.08 ± 3.13
6.18 ± 1.91
16.61 ± 0.05
19.62 ± 0.90
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The previously collected solution flowing through the Bond Elut Plexa SPE column for
Sanilac, SARC1, SMARC1-PN1 and SMARC1N-PN1 BPIH was reloaded into the C18
column and eluted with 25% increments of ACN + 0.1% TFA. As shown in Table 3 15, active compounds with antioxidant activity in all four genotypes were detected in the
fraction eluted with 0% and 25% ACN + 0.1%TFA. For Sanilac and SMARC1-PN1, the
active antioxidant compounds were also detected in the C18 flow-through fraction. No
antioxidant compounds were found in higher ACN concentration fractions for all four
varieties.

Table 3 - 15: The Net AUC corresponding to the Sanilac, SARC1, SMARC1-PN1,
SMARC1N-PN1 BPIH, and their fractions; n = 3.

Sanilac

BPIH
(Mean
± SD)
38.10
± 1.07

Bond Elut
Plexa
flowthrough
(Mean ±
SD)
37.32 ±
1.49

C18
flowthrough
(Mean
± SD)
9.95 ±
0.23

0%
ACN +
0.1%
TFA
(Mean ±
SD)
13.41 ±
0.84

25% ACN
+ 0.1%
TFA
(Mean ±
SD)
14.97 ±
1.23

SARC1

42.11
± 0.67

35.96 ±
1.26

6.96 ±
0.52

14.07 ±
0.63

SMARC1PN1

41.71
± 0.36

37.40 ±
1.15

10.68 ±
1.17

SMARC1NPN1

45.51
± 0.72

34.12 ±
1.19

5.26 ±
0.29

Variety

50%
ACN +
0.1%TFA
(Mean ±
SD)

75%ACN
+
0.1%TFA
(Mean ±
SD)

100%ACN
+
0.1%TFA
(Mean ±
SD)

<0.63

<0.63

<0.63

12.14 ±
0.39

<0.63

<0.63

<0.63

29.46 ±
0.31

13.09 ±
1.38

0.67 ±
0.30

1.33 ±
1.01

<0.19

18.96 ±
0.90

19.75 ±
0.80

<0.92

2.51 ±
0.45

<0.19
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The peptide quantification of each fraction for all four common bean caltivars were tested
and presented in Table 3 - 16. Most peptides were eluted by 0% or 25% ACN + 0.1% TFA,
and contained active compounds which had antioxidant capacity. Moreover, the peptide
concentration appeared to have a positive relationship with the antioxidant capacity (Table 3
- 15), suggesting that the active antioxidant compounds in the four common bean varieties
were likely derived from peptides.
Table 3 - 16:
SMARC1-PN1, SMARC1N-PN1 BPIH, and their fractions; n=3.

Sanilac

Bond Elut C18 flow- 0% ACN + 25% ACN 50%ACN + 75%ACN + 100%ACN
BPIH Plexa flow- through 0.1% TFA + 0.1%
0.1%TFA 0.1%TFA + 0.1%TFA
(Mean
through
(Mean ± (Mean ± TFA (Mean (Mean ±
(Mean ±
(Mean ±
± SD) (Mean ± SD) SD)
SD)
± SD)
SD)
SD)
SD)
5388.3 3277.9 ±
469.2 ± 867.2 ±
1207.0 ±
± 140.8
126.8
27.5
11.4
23.2
<5.7
<5.7
<5.7

SARC1

4598.5
± 22.9

2686.0 ±
100.8

286.2 ±
1036.5 ±
27.5 912.7 ± 9.2
10.8

<5.7

<5.7

<5.7

SMARC1PN1

5172.9
± 238.5

3005.3 ±
152.0

349.2 ±
18.3

1022.7 ±
2.6

1211.2 ±
32.2

<5.7

<5.7

<5.7

SMARC1N- 5464.3
PN1
± 340.7

3117.2 ±
54.7

174.3 ±
57.7

920.2 ±
30.1

1158.4 ±
11.5

<5.7

<5.7

<5.7

Variety
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Chapter 4: Discussion
4.1 Evaluate the benefits of common bean
4.1.1 Peptide quality of the common bean
The primary purpose of this project was to evaluate if peptides derived from cooked common
bean after exposure to conditions mimicking human digestion, had antioxidant capacity,
DPP-IV enzyme inhibition, -a

-glucosidase inhibition, antimicrobial, and anti-

lipogenic properties, and to identify any bioactive peptides. SDS-PAGE is a common and
effective way to separate proteins based on their molecular weight and electrophoretic
mobility. As expected, almost all proteins were digested into small peptides (<10 kDa) for
four cultivars after pepsin and pancreatin digestion, based on the SDS-PAGE results of the
protein profiles for the digested beans (Figure 3 - 1). Table 3 - 2 revealed that at least 40% of
the substances in the BPIH solution were peptides. The molecular mass profiles obtained
from MALDI-TOF/TOF further confirmed that the proteins were digested to small peptides,
and over 50% of them were in the molecular mass range from 600-1000 Da for the four
cultivar varieties (Table 3 - 1). According to Montoya et al. (2008), even though the
nutritional value of common bean protein is low due to poor digestibility, thermal treatment
can denature the proteins, breaking the

structure and making them more open,

thereby increasing the exposure of hydrophobic residues. This structural modification allows
gastrointestinal enzymes to break the proteins down more thoroughly into peptides by
reaching protein sites that the enzymes cannot naturally access, thereby increasing the
digestibility of common bean, and producing more small bioactive peptides that the human
body can absorb (Nosworthy et al., 2018).

4.1.2 Evaluation of the non-nutritional values of common bean
4.1.2.1

Antioxidant capacity of common bean peptides

Reactive oxygen species (ROS) are by-product of aerobic metabolism, including peroxides,
superoxide, and other oxygen-containing free radicals. They are very active because of the
presence of an unpaired electrons. ROS are produced in large quantities by aerobic organisms
in the process of aerobic respiration under normal conditions or in the process of innate
immunity to defend against foreign pathogens (Luna-Vital et al., 2015). Many previous in
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vitro and in vivo studies indicated that common bean protein hydrolysates have antioxidant
capacity and identified the corresponding peptides (Ariza-Ortega et al., 2014; BetancurAncona et al., 2014; Valdez-Ortiz et al., 2012). Glutathione is an abundant thiol-containing
tripeptide produced in most organisms that can undergo oxidation and reduction cycles to
detoxify ROS (Pompella et al., 2003). Since cysteine is the only amino acid that contains
thiol groups, I would have expected that SMARC1N-PN1, which has a higher combined
methionine-cysteine content, has higher antioxidant capacity than other cultivars that lack
sulphur amino acids. As expected, the line SMARC1N-PN1 BPIH had the highest ORAC
value among other cultivars (Table 3 - 6) since the principle for ORAC assay is the hydrogen
atom transfer process, which is similar to how glutathione undergoes reversible disulfide
bond formation to detoxify ROS. However, the BPIH of SMARC1N-PN1 did not perform
well in the FRAP assay compared with other cultivars (Table 3 - 7). Since the FRAP assay
analyzed the antioxidant capacity based on the single-electron transfer process, it was
revealed that SMARC1N-PN1 BPIH was weaker at the donation of an electron to balance
free radicals compared with Sanilac, SARC1, and SMARC1-PN1 BPIH. Although different
antioxidant experiments cannot be compared because of the different chemistries of each
assay, the SMARC1N-PN1 BPIH was considered the best cultivar among four lines against
free radicals because the chemistry of the ORAC assay was similar to how glutathione
functions in the human body to neutralize free radicals.
Many former studies indicated and identified many small bio-peptides of common bean such
as sequence

in

in

Great N bean, (Mojica et al., 2015). Our results presented here also suggest that the active
compounds in BPIH were probably peptides because the active compounds were all found in
the fractions that contained a large number of peptides. The concentration of peptides was
positively related to antioxidant capacity in cultivars, demonstrating that a mixture of
peptides might work together towards enhanced antioxidant capacity (Table 3 - 15 and Table
3 - 16).

4.1.2.2

Antimicrobial property of the common bean

Bacterial drug resistance leads to serious health problems worldwide due to the long-term use
and the abuse of traditional antibiotics, and it causes at least 700,000 deaths annually
(Pokharel et al., 2020). Thus, identification of new antibiotics or other new antibacterial
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compounds

is

attracting

increasing

attention

from

scientists

worldwide. Because

antimicrobial peptides are not easily affected by the evolution of bacterial resistance, they are
considered a promising class of new antibiotics and provide a healthier way to protect the
human body against pathogens (El Shazely et al., 2020). My results showed that Grampositive bacteria, B. subtilis and S. aureus, appear to be sensitive to BPIHs, and all cultivars
had similar antimicrobial properties for these two bacteria. However, all common bean BPIH
had little to no inhibitory effect on any kind of gram-negative bacteria (Figure 3 - 6). The
reason might be related to the different cell wall compositions of gram-positive and gramnegative bacteria. The cell wall for gram-positive bacteria is simpler than gram-negative
bacteria, consisting only of teichoic acid and peptidoglycan to encase the cell membrane. In
contrast, gram-negative bacteria have not only two layers of cell membranes separated by
periplasmic space composed of murein lipoprotein and peptidoglycan, but also have
membrane protein and porin in the outer membrane, which is covered by lipid A, O antigen
and lipopolysaccharide (Beveridge, 1999; Navarre and Schneewind, 1999). In this study, the
more complex composition of the gram-negative bacteria cell wall seems to protect the
bacteria from BPIH.
My results suggest that the active antimicrobial compounds in BPIH were probably not
peptides because the active compounds were found in fractions containing few peptides
(Figure 3 - 14 and Table 3 - 11). Since most of the active compounds with antimicrobial
activity were abundant in plates treated with the 50-100% MeOH fractions (Figure 3 - 15),
which had similar elution properties to the active compounds exhibiting DPP-IV enzyme
inhibition (Table 3 - 8 and Figure 3 - 11), we can predict that the active antimicrobial
compounds might also belong to the lipid class, while few of the literature to date for
common bean has focused on lipids. To date, many bio-active common bean antimicrobial
peptides against human pathogens have been identified, such as the peptide sequence
KTCENLADTFRGPCFATSNC in King Pole Bean that can inhibit Candida albicans
(Wong et al., 2012). There were some articles related to the potential of lipids against
bacteria. For example, Hinson and Cresswell (2009) and Anand et al. (2012) pointed out that
some mammalian lipid droplets might be the first line of defense against the invasion of
pathogens by laced with many antimicrobial proteins. Bosch et al. (2020) further confirmed
this point by injecting lipopolysaccharide into laboratory mice to simulate bacterial infection
and isolated lipid droplets from these mice. They found that lipid droplets isolated from mice
injected lipopolysaccharide accumulated several interferon-inducible proteins, including
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cathelicidin, which made them have better antimicrobial capacity than lipid droplets isolated
from mice that injected normal saline. Plants lipids, such as fatty acid methyl ester in the
leaves of sea purslane, S. maritima, and S. monoica (Chandrasekaran et al., 2008;
Chandrasekaran et al., 2011), fatty acids in the seeds of summer asphodel (Fafal et al., 2016),
and sterol in the seeds of date palm (Sundar et al., 2017), are reported to have potential
antimicrobial activity previously. Our result also might indicate lipids found in common bean
as a potential antibacterial resource against drug resistance. However, information for the
possible antimicrobial compounds we found in this project is limited concerning the nature of
the bioactive molecules, so further investigation is needed.

4.1.2.3

DPP-IV inhibition of common bean

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are
two important incretins that respond to an increased concentration of glucose in the digestive
tract lumen to stimulate insulin release, thus lowering blood glucose (Zhong et al., 2013).
Dipeptidyl peptidase-IV(DPP-IV) rapidly degrades these two incretins, which helps prevent
the overproduction of insulin and hypoglycemia. To date, the inhibition of the enzyme DPPIV is the target of several oral hypoglycemics anti-diabetic medications, including Januvia
(sitagliptin), Novartis (vidagliptin), Onglyza (saxagliptin), Nesina (alogliptin), etc. (Parmar et
al., 2012). As outlined in Figure 3 - 5, SMARC1N-PN1 had the lowest IC 50 value (0.86
mg/mL freeze-dry BPIH extract) for DPP-IV inhibition among the four cultivars. SARC1 had
the highest IC 50 value, while Sanilac and SMARC1-PN1 had similar IC 50 value.
Many former studies have indicated that common bean protein hydrolysates have DPP-IV
inhibition properties, and identified many small bio-peptides, such as the sequences FATGT
and

in Black bean, and

in Navy bean, etc. (Mojica et al.,

2015; Oseguera-Toledo et al., 2015; Oseguera-Toledo et al., 2016). Unexpectedly, my results
revealed that the active compounds that had DPP-IV inhibition property in BPIH were
probably not peptides (Figure 3 - 13). According to the LC-MS/MS identification, the DPPIV enzyme may be inhibited by lipids found in common bean, such as monoacylglycerol
(MG), phosphatidylglycerol (PG), phosphatidylethanolamine (PE), and phosphatidylcholine
(PC) (
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Table 3 - 10). It is a new discovery in this area with no similar report in the literature, at least
to my knowledge, so further in vitro and in vivo experiments are needed to prove this finding.
One of the active compounds we identified was possibly MG (0:0/18:3/0:0), its putative
formula was C21H36O4, and it belongs to monoacylglycerols, which are composed of glycerol
linked to a fatty acid by an ester bond (Long et al., 2009). MG (0:0/18:3/0:0) was a potential
important compound since it was only detected in the 70% MeOH fraction and SMARC1NPN1 BPIH (ID 37 in Table 3 - 9). MG (0:0/18:3/0:0) can be found in low concentration (1 3%) in the derivatized common bean fatty acid profile (David et al., 2019). Since the
powerful emulsifier of monoacylglycerol can cause membrane damage

et al.,

2013), the strong detergent of MG (0:0/18:3/0:0) might relate to the DPP-IV enzyme
inhibition based on the fact that DPP-IV enzyme is expressed on the surface of most cell
types. In future studies, it would be of interest to purify this compound from the BPIH or
obtain this compound from a commercial manufacturer and test for the DPP-IV inhibition
individually.
PG (16:0/0:0) was another possible active compound identified by LC-MS/MS; the putative
formula of this compound is C22H45O9P and it belongs to phosphatidylglycerols. This
compound was only detected in the 70% MeOH fraction but not in the SMARC1N-PN1
BPIH extract (row ID 24 in Table 3 - 9). Consider that the environment in BPIH is more
complex than in fractions, some compounds might have been observed in a fraction but
below the limit of detection or at low levels in the BPIH extract that can be detected. Thus,
PG could still be a potential candidate for inhibiting DPP-IV enzyme. PG is an anionic
phospholipid and has been found in almost all organisms (Wada and Murata, 2007). Previous
studies mainly focused on how PG in chloroplasts can help to complete photosynthetic light
reactions and electron transport because it is the only phospholipid found in the thylakoid
membrane of the chloroplast to play a special role in photosynthesis (Gombos et al., 2002;
Hagio et al., 2002; Sato et al., 2000), while the finding in my project might reveal a new
potential function of PG in common bean seeds. Future work can focus on purifying this
compound from the BPIH or buy this compound and test for DPP-IV inhibition individually.
PE (18:0/0:0) was identified as a possible active compound; its putative formula is
C23H48NO7P and it belongs to phosphatidylethanolamines. It was only detected in the 70%
MeOH fraction and not in the SMARC1N-PN1 BPIH (row ID 22 in Table 3 - 9). PE is a
major lipid widely distributed in the bilayers membrane of plant cells, and it is also the
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second most abundant phospholipid in the plant after phosphatidylcholine (Mizoi et al., 2003).
The content of PE in mitochondrial membrane is particularly high, especially in the inner
membrane, where its content is much higher than that in other organelles, this suggests that
PE contributes to many mitochondria functions such as oxidative phosphorylation through
the electron transport chain (Ball et al., 2018). According to my results, PE (18:0/0:0) might
also have DPP-IV inhibition properties. Future studies involve purification of this compound
from the BPIH or purchasing this compound and test for the DPP-IV inhibition individually.
Five more different phosphatidylcholines (PC) were identified as possible active compounds
that may have inhibitory properties for the DPP-IV enzyme, and their putative formula are
C29H60NO7P, C29H60NO8P, C31H64NO7P, C42H76NO8P, and C44H78NO8P (row ID 2, 14, 1, 18,
3, respectively, in Table 3 - 9). Phosphatidylcholine mainly exists in the cells of animals and
plants and may offer many benefits for human health. It is the major component of the cell
membrane of living organisms. The oilseed crops are usually rich in phosphatidylcholine.
Soybean lecithin is a good example of phosphatidylcholine, it constitutes not only an
important part of the biological membrane but also is a source of choline and fatty acids,
which play key roles in maintaining the physiological activity of biological membranes and
the normal metabolism of the human body (List, 2015). In the literature are reports that PC
can maintain liver health, cardiovascular, and brain health (Lieber et al., 1990; Miller, 2002;
Smith et al., 2016), while the findings in my project might reveal a new potential function of
PC.

4.2 Possible reasons that affect active common bean peptides
For the digested common bean peptides after cooking, there is ample literature indicating that
they work for -amylase and -glucosidase inhibition (Mojica et al., 2015; Oseguera-Toledo
et al., 2015) and DPP-IV enzyme inhibition properties (Mojica et al., 2015; Mojica and de
Mejía, 2016; Oseguera-Toledo et al., 2016). Soybean peptides were identified that had antilipogenic property (Martinez-Villaluenga et al., 2008; Martinez-Villaluenga et al., 2009),
which prompted us to explore if common bean digested peptides also have similar antilipogenic ability. However, common bean peptides isolated in this study did not appear to
exhibit enzyme inhibition properties that listed above. The possible reasons might relate to
the cooking process and bean cultivars used in this project.
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4.2.1 Cooking process might influence the quality and nutritional
value of common beans
In many developing countries where animal proteins are expensive, common bean has
become a staple food for many low-income people in both rural and urban areas because of
the high protein content (19-27%) and other nutrients (Lima et al., 2005). Despite its high
nutritional value and its functional properties, the common bean does have some drawbacks,
this

-to-

(HTC) phenomenon due to the deterioration of the

texture and flavor and the prolonged cooking time required due to the hardening of the beans
(Oseguera-Toledo et al., 2015). The HTC phenomenon reduces the nutritional value of
common been seeds by inhibiting the separation of cells during cooking, which affects the
texture of seeds after cooking and limits the breakdown of proteins by digestive enzymes
(Batista et al., 2010).
Different cooking processes can significantly affect the nutritional value of common bean.
According to Batista et al. (2010), extrusion during cooking of common bean could increase
the digestibility of proteins and starch by reducing the activity of antinutritional factors such
-amylase inhibitors, which might explain why the BPIH for the four cultivars
did not inhibit the -amylase

-glucosidase enzyme (Error! Reference source not found.

and Figure 3 - 2). Moreover, previous studies used additional steps before cooking the bean,
such as soaking the beans overnight to remove the hull (Oseguera-Toledo et al., 2015);
blanching the beans and putting them under high pressure or oven-dry before cooking (also
called precooking) (Mojica et al., 2015); or grinding beans into powder (Batista et al., 2010).
Some studies suggested cooking beans by autoclaving instead of boiling them (OsegueraToledo et al., 2015), or performed protein extraction first from the ground common bean
powder, then autoclaved at a high temperature and pressure before protein hydrolysis (Mojica
and de Mejía, 2016). All these differences might explain why there were no active peptides
found in my project that exhibited -amylase and -glucosidase inhibition, DPP-IV enzyme
inhibition, antimicrobial, or anti-lipogenic properties.
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4.2.2 Bean varieties influence the quality and nutritional value of
beans
Based on the fact that the protein profiles vary in different common bean cultivars, the
common bean cultivars in this project might also explain why there were not active peptides
exhibiting -amylase and -glucosidase inhibition, DPP-IV enzyme inhibition, antimicrobial,
or anti-lipogenic properties. Previous research has focused on the well-known common bean
market classes such as

lack , Red , Na

Great Northern

and Pinto , which the

main storage proteins found in these commercial cultivars is phaseolin (Batista et al., 2010;
Mojica et al., 2015), and indeed found bioactive peptides associated with the capacities listed
above. The germplasm lines SARC1, SMARC1-PN1 and SMARC1N-PN1 are relatively new
and less studied. This project might indicate that different common bean genotypes may have
different abilities, which require more experiments to focus on a specific genotype and
confirm this hypothesis.
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Chapter 5: Conclusions
5.1 Concluding remarks and Future studies
As one of the most common commercial crops, the common bean provides adequate nutrition,
with relatively high protein content and several health benefits. Although numerous studies
have revealed health benefits from common bean consumption, few have focused on
common bean bioactive peptides (from cooked and digested beans) and attempted to identify
if they have -amylase and -glucosidase inhibition, antioxidant capacity, DPP-IV inhibition,
antimicrobial ability, and anti-lipogenic properties. The goals of this project were to
characterize and identify bioactive peptides specialized for antioxidant capacity, DPP-IV
inhibition, -amylase and -glucosidase inhibition, and antimicrobial ability derived from the
digestion of cooked common bean extracts, and determine the anti-lipogenic ability in
cultured murine adipocyte cells. Our results indicate that cooked common bean indeed had
some antioxidant, antimicrobial and anti-diabetic properties, but lacked

-amylase,

-

glucosidase inhibition, and anti-lipogenic ability. Moreover, SMARC1N-PN1 had higher
antioxidant capacity, DPP-IV inhibition, and antimicrobial properties than the other 3
varieties.
As expected, the active compounds for antioxidant capacity were probably a mixture of small
peptides because the majority of peptides were eluted into the active fractions for antioxidant
capacity. However, the active compounds for antimicrobial properties were probably not
peptides. This is a potentially new finding for antibacterial resources against drug resistance,
but the information is limited concerning the nature of the bioactive molecules, requiring
further investigation. DPP-IV may be inhibited by lipids, such as monoacylglycerols,
phosphatidylglycerol,

phosphoethanolamine,

and

phosphatidylcholine,

which

is

an

unexpected result and new discovery in this area, with no similar report in the literature to the
best of my knowledge. Future work should focus on testing each identified compound for the
DPP-IV inhibition individually to confirm this finding.
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